Document:

EX-10.1

 Exhibit 10.1 

VIRACTA THERAPEUTICS, INC. 

EXECUTIVE EMPLOYMENT AGREEMENT 

This Executive Employment Agreement (this “Agreement”) by and between Viracta Therapeutics, Inc. (the
“Company”) and Mark Rothera (“Executive”) is effective as of September 19, 2022 (the “Effective Date”). 

1. Duties and Scope of Employment. 

(a) Positions, Authority and Duties. Executive will serve as Chief Executive Officer and President of the Company. Executive will have
the authority, responsibilities and duties as are customary for the Chief Executive Officer of a publicly traded company in the United States, and such additional authority, responsibilities and duties, consistent with Executive’s position
within the Company, as will reasonably be assigned to Executive by the Company’s Board of Directors (the “Board”). The period of Executive’s employment from the Effective Date is referred to herein as the
“Employment Term.” 
 (b) Board Membership. Executive shall be appointed to the Board as of the Effective Date and
shall serve as a member of the Board during the Employment Term, subject to any required shareholder approval. For each annual meeting of the shareholders at which Executive’s term expires that occurs during the Employment Term, Executive will
be nominated for re-election as a member of the Board. 
 (c) Obligations. During the
Employment Term, Executive shall perform Executive’s duties faithfully and to the best of Executive’s ability and shall devote substantially all of Executive’s business efforts and time to the Company. For the duration of the
Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity for any direct or indirect remuneration which would conflict or interfere with the performance of such services without the prior
approval of the Board. Notwithstanding the foregoing, Executive may participate fully in social, charitable, civic and investment activities (including service as an officer or a director of an entity related to such activities). In addition to
being permitted to engage in such social, charitable, civic and investment activities, Executive shall have the right, with the prior written consent of the Board, to serve as a member of the board of directors or comparable governing bodies
(including any board committees) of up to two for-profit businesses, one of which shall be satisfied by Executive’s continued service on the board of GenPharm. 

(d) Work Location. Executive’s primary work location will be his home office in New Hampshire. Executive shall allocate sufficient
time working in person at the Company’s headquarters in Cardiff, California, while incorporating considerations such as pandemic lockdowns, travel restrictions, social distancing measures, virtual conferences and internet-based meetings against
business impact and timely execution on deliverables. To such an end, Executive shall dedicate a minimum of a third (1/3rd) of his time on a quarterly basis for the conduct of on-site work-related endeavors,
including, but not limited to working at the Company’s headquarters, medical, scientific and investor conferences, fund raising, clinical trials and vendor related activities as well as travel related thereto. 

(e) At-Will Employment. The parties agree that Executive’s employment with the Company
will be “at-will” employment and may be terminated at any time with or without cause or notice. Executive understands and agrees that neither Executive’s job performance nor promotions,
commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive’s employment with the Company. However, as described in this
Agreement, Executive may be entitled to severance benefits depending on the circumstances of Executive’s termination of employment with the Company. 

 2. Compensation. 

(a) Base Compensation. During the Employment Term, the Company will pay Executive an annual salary of five hundred eighty thousand six
hundred fifty Dollars ($580,650.00) as compensation for Executive’s services (the “Base Salary”), which will be paid periodically in accordance with the Company’s normal payroll practice, subject to Section 19.
Executive’s salary will be subject to review and adjustments may be made in the Company’s sole discretion, except that Executive’s Base Salary may not be reduced without notice and written consent of Executive. 

(b) Sign on Bonus and Relocation Reimbursement. 

(i) Sign on Bonus. Executive will be paid a sign-on bonus of $100,000 (the
“Sign-on Bonus”), subject to Section 19. The Sign-on Bonus will be paid within 30 business days following the Effective Date. If Executive
voluntarily terminates his employment with the Company, other than for Good Reason, before the date that is eighteen (18) months after the Effective Date, Executive agrees to repay to the Company a prorated portion of the amount of the Sign-on Bonus within (thirty) 30 days following his last day with the Company. The amount of such repayment would represent the portion of the Sign-on Bonus received by
Executive that has not been earned as of the date of the voluntary termination. For clarity, the Sign-on Bonus will be earned based on the number of days that Executive has been employed by the Company divided
by the number of days in the (eighteen) 18-month period beginning on the Effective Date. 

(ii) Relocation Reimbursement. The Company will reimburse Executive for reasonable and bona fide costs for up to three
(3) exploratory trips to the San Diego, California metropolitan area, for Executive and his family (namely, Sahel Golestan), up to a combined maximum of $7,500. If (x) Executive notifies the Company during the first twelve (12) months
of the Employment Term of his intent to relocate his current principal place of residence to the San Diego, California metropolitan area and (y) so relocates his current principle place of residence no later than the date that is (eighteen) 18
months after the Effective Date, subject to Section 19, the Company will reimburse reasonable qualified relocation costs of temporary housing and a rental car for up to three (3) months (the “Relocation Reimbursement”).

 If Executive voluntarily terminates Executive’s employment with the Company other than for Good Reason before the first anniversary
of the start of Executive’s employment with the Company, Executive agrees to repay to the Company 100% of the amount of the Relocation Reimbursement within thirty (30) days following the Executive’s last day with the Company. If
Executive voluntarily terminates Executive’s employment with the Company other than for Good Reason after the first anniversary but before the second anniversary of the start of the Executive’s employment with the Company, Executive agrees
to repay to the Company a prorated portion of 50% of the amount of the Relocation Reimbursement within thirty (30) days following the Executive’s last day with the Company. The amount of such repayment would represent the portion of the
Relocation Reimbursement received by Executive that has not been earned as of the date of the voluntary termination. For clarity, the Relocation Reimbursement will be earned based on the number of days that Executive has been employed by the Company
divided by the number of days in the two-year period beginning on the date Executive’s employment begins. 

After the first anniversary of the employment start date, Executive will have to make a special request to the Board for any financial
assistance with respect to relocation. 
 (c) Employee Benefits. During the Employment Term, Executive will be entitled to
participate in the employee benefit plans and programs currently and hereafter maintained by the Company of general applicability to other senior executives of the Company, including, without limitation, the Company’s 401(k) retirement plan,
group medical, dental, vision, disability, life insurance, and flexible-spending account plans, if any, pursuant to the terms and conditions of such plans. The Company reserves the right to cancel or change the benefit plans and programs it offers
to its employees at any time. 

 (d) Paid Time Off/Vacation. During the Employment Term, Executive will be entitled to
accrue twenty-five (25) days of paid time-off/vacation annually, in accordance with the Company’s paid-time off policies. Accrued and unused vacation will carry over from year to year, as required by
applicable California law, up to a cap of no more than 30 days. Notwithstanding such policies, (i) Executive’s full twenty-five (25) days of paid time-off/vacation for Executive’s first
year of employment will accrue on the Effective Date; and (ii) paid time-off/vacation to be used at the discretion of the Executive, subject to business needs and approval of the Board Chairman. 

(e) Target Bonus. During the Employment Term, Executive will be eligible to receive an annual bonus of up to fifty-five percent (55%)
of Executive’s Base Salary (the “Target Bonus”), subject to Section 19, upon achievement of performance objectives to be determined by the Board or an authorized committee thereof (the “Committee”) in its
sole discretion but in consultation with Executive. Any bonus payable (the “Actual Bonus”) will be paid as soon as practicable after the Board or Committee determines such bonus has been earned, but in no event will any such
bonus be paid after March 15 following the calendar year in which such bonus is earned. Except as set forth in Section 5 below, in order to earn any bonus, Executive must be employed by the Company on the date the bonus is paid. Except as
set forth in Section 5 below, Executive will not be eligible for a bonus if Executive’s employment with the Company terminates prior to the payment date, regardless of whether Executive or the Company initiates the termination, and
independent of whether the termination is with or without cause. For the Company’s 2022 fiscal year, Executive is guaranteed not less than the Target Bonus, prorated for the portion of the year that the Executive was employed by the Company.

 3. Equity. 
 (a)
Inducement Option. As soon as practicable following the Effective Date, subject to approval by the Compensation Committee of the Board, as a material inducement to Executive’s acceptance of employment with the Company, Executive will be
granted a non-statutory stock option to purchase 1,375,000 shares of the Company’s common stock, with an exercise price per share equal to the per share fair market value of the Company’s common
stock on the date of grant (the “Initial Option”). The Initial Option will be granted pursuant to the Viracta Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Option Plan”). The Initial Option
will vest with respect to twenty-five percent (25%) of the total number of shares of the Company’s common stock subject to the Initial Option on the first anniversary of the Effective Date, and with respect to
one-forty-eighth (1/48) of the total number of shares of the Company’s common stock subject to the Initial Option on the last day of each one-month period of
Executive’s service to the Company thereafter. The Initial Option will be subject to the terms and conditions of the Option Plan and any form of stock option agreement issued thereunder, provided that in the event of any conflict between the
terms of thereof and this Agreement, including with respect to the acceleration rights described in Section 5, this Agreement shall prevail. 

(b) Additional Equity Awards. Executive will be eligible to receive additional awards of stock options, restricted stock units, or
other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board or the Committee will determine in its discretion whether Executive will be granted any such equity awards and the terms of any
such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time. 
 4.
Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in the furtherance of or in connection with the performance of Executive’s duties hereunder, in accordance with
the Company’s expense reimbursement policy as in effect from time to time, subject to the following: 

 (a) Air Travel. Business class, or first class if business class is not available,
may be used for domestic air travel outside of California, Arizona, and Nevada. 
 (b) Train Travel. All train travel may be booked
in business class. 
 (c) Lodging. Guidelines for reimbursable lodging expenses, including taxes, target a maximum of $375 per night
except in high priced cities (i.e., New York, Boston, Miami, Chicago, San Francisco Bay area, San Diego, Los Angeles, Washington, D.C., and Vancouver) and outside of North America where they should target a maximum of $475 per night. 

(d) Business Meals. Reasonable business-related travel dining expenses (including taxes and gratuity not to exceed 20%) are
reimbursable. Costs of providing meals to actual or prospective customers, suppliers, applicants, candidates, or other non-Company individuals for business purposes are reimbursable. Personal meals and
incidental expenses incurred while traveling on business are reimbursable, including taxes and tips, up to the following daily maximums: $150 (North America/Europe/Latina America); $200 (Asia Pacific, not including Japan); and $225 (Japan/UK). 

5. Severance Benefits; Change in Control Benefits. 

(a) Non-CIC Qualified Termination. If the Company terminates Executive’s employment with
the Company outside of the Change in Control Period (as defined below) other than for Cause (as defined below), death or Disability (as defined in the Company’s 2021 Equity Incentive Plan (the “Plan”)), or Executive resigns
from Executive’s employment with the Company for Good Reason (as defined below) (such a termination, a “Qualified Termination”), then, subject to Section 6, Executive will be entitled to the following: 

(i) continued payment of Executive’s annual Base Salary, at the level in effect immediately prior to Executive’s
termination date, for a period of fifteen (15) months following the date of the Qualified Termination, with the first payment payable through the Company payroll within thirty (30) days following the effective date of the Release (as
defined below) (and to include any amounts that otherwise would have been paid between the termination date and the payment date); 

(ii) reimbursement by the Company for the cost of premiums for Executive and Executive’s covered dependents, if any, for
group health insurance continuation coverage under Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) for up to fifteen (15) months following Executive’s termination of employment
(the “COBRA Premium Reimbursement”), provided that (x) Executive and Executive’s covered dependents timely elect and remain eligible for continued coverage under COBRA and (y) such COBRA Premium Reimbursement does not
result in excise tax penalties for the Company under applicable laws (including, without limitation, Section 2716 of the Public Health Service Act). Notwithstanding the preceding, if the Company determines in its sole discretion that it cannot
provide COBRA reimbursement benefits without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will instead provide the Executive a taxable payment in an amount
equal to the monthly COBRA premium that the Executive would be required to pay to continue the Executive’s group health coverage in effect on the date of termination of employment (which amount will be based on the premium for the first month
of COBRA coverage), which payments will be made regardless of whether the Executive elects COBRA continuation coverage and will commence in the month following the month of the termination date and continue for the period of months indicated in this
section; 

 (iii) payment of any Actual Bonus with respect to a fiscal year of the
Company preceding the termination date that has not been paid as of the termination with the payment paid on the first Company payroll date following the effective date of the Release; 

(iv) payment of the Target Bonus for the fiscal year of the Company in which the termination date occurs, at the level in
effect immediately prior to Executive’s termination date, pro-rated to reflect the number of days in such fiscal year that Executive provided service, payable in a lump sum on the first Company payroll
date following the effective date of the Release; and 
 (v) the right to exercise Executive’s stock options granted by
the Company until the close of business on the date that is the earlier of (x) twelve (12) months after executive’s termination date or (y) the term/expiration date of the stock option. 

(b) CIC Qualified Termination. Upon a Qualified Termination occurring during the period beginning three (3) months prior to a
Change in Control (as defined in the Plan) and ending twelve (12) months following a Change in Control (the “Change in Control Period”), then, in lieu of the severance benefits described in Section 5(a) above and subject
to Section 6, Executive will be entitled to the following: 
 (i) a lump sum payment equal to eighteen (18) months
of Executive’s annual Base Salary, at the level in effect immediately prior to Executive’s termination date, paid on the first Company payroll date following the effective date of the Release (as defined below); 

(ii) COBRA Premium Reimbursement for up to eighteen (18) months following Executive’s termination of employment,
provided that (x) Executive and Executive’s covered dependents timely elect and remain eligible for continued coverage under COBRA and (y) such COBRA Premium Reimbursement does not result in excise tax penalties for the Company under
applicable laws (including, without limitation, Section 2716 of the Public Health Service Act). Notwithstanding the preceding, if the Company determines in its sole discretion that it cannot provide COBRA reimbursement benefits without
potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will instead provide the Executive a taxable payment in an amount equal to the monthly COBRA premium that the
Executive would be required to pay to continue the Executive’s group health coverage in effect on the date of termination of employment (which amount will be based on the premium for the first month of COBRA coverage), which payments will be
made regardless of whether the Executive elects COBRA continuation coverage and will commence in the month following the month of the termination date and continue for the period of months indicated in this section; 

(iii) payment of any Actual Bonus with respect to a fiscal year of the Company preceding the termination date that has not
been paid as of the termination, payable through the Company payroll within thirty (30) days following the effective date of the Release; 

(iv) payment of 150% of the Target Bonus for the fiscal year of the Company in which the termination date occurs, at the level
in effect immediately prior to Executive’s termination date, payable in a lump sum on the first Company payroll date following the effective date of the Release; and 

(v) 100% of the unvested portion of any stock options or other equity award held by Executive that remain outstanding as of
immediately prior to the date of such Qualified Termination shall immediately vest and become exercisable (but, in no case, will more than 100% of the shares subject to any award vest and become exercisable); provided, however, that any stock
options or other equity award held by Executive that, at any time such equity award is outstanding, is subject to performance-based vesting, will vest assuming target performance. For purposes of clarity, any stock options or other equity award held
by Executive as of any Qualified Termination not within the Change in Control Period will remain outstanding for not less than three (3) months following such Qualified Termination (or, if longer, the period described in Section 5(a)(v))
in order to give effect to this provision. 

 (c) Non-Duplication of Payment or Benefits.
For purposes of clarity, in the event of that a Change in Control occurs within three (3) months following a Qualified Termination, any severance payments and benefits to be provided to the Executive under Section 5(b) will be reduced by
any amounts that already were provided to the Executive under Section 5(a). 
 (d) Termination for Cause, Death or Disability;
Voluntary Resignation without Good Reason. If Executive’s employment with the Company terminates voluntarily by Executive for any reason (except upon resignation for Good Reason), for Cause by the Company or due to Executive’s death or
Disability, then (i) all vesting will terminate immediately with respect to Executive’s outstanding equity awards and (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to
amounts already earned, as described in Section 5(e); provided, however,, if Executive’s employment with the Company terminates due to Executive’s death or Disability, then Executive or his estate will receive a payment equal to the
Target Bonus in the year of termination, pro-rated to reflect the number of days in the fiscal year of termination that Executive provided service, and paid with the first payroll date following the date of
termination, and such termination shall be considered a Qualified Termination for purposes of Section 5(a)(v) or 5(b)(v), as applicable. 

(e) Amounts Payable on All Terminations. If Executive’s employment with the Company terminates for any reason, Executive shall be
entitled to received, in addition to the amounts set forth above, all amounts already earned, including (i) Base Salary through the date of termination, (ii) vacation and paid time off earned but unused through the date of termination,
(iii) reimbursement of expenses properly incurred prior to termination, and (iv) any benefits paid or provided upon or following termination pursuant to any employee benefit plan or policy in accordance with the terms thereof. Except as
otherwise expressly provided herein, the Executive’s rights with respect to the Initial Option and any other equity awards shall be governed by the terms of the applicable plan and award agreement. 

6. Conditions to Receipt of Payments; No Duty to Mitigate. 

(a) Separation Agreement and Release of Claims. The receipt of any payments or benefits pursuant to Section 5, other than the
amounts described in Section 5(e), will be subject to Executive signing and not revoking a separation agreement and release of claims in a form reasonably satisfactory to the Company (the “Release”) and provided that
such Release becomes effective and irrevocable no later than sixty (60) days following the termination date (such deadline, the “Release Deadline”). Notwithstanding the foregoing, Executive will not be required to accept a
Release that (i) extends the post-employment restrictive covenants applicable to Executive, (ii) waives rights to seek indemnification under any D&O policy, indemnification agreement between the parties, or the Company’s bylaws or
(iii) waives rights as a shareholder of the Company. If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under this Agreement, other than as provided in Section 5(e).
In no event will severance payments or benefits be paid or provided until the Release becomes effective and irrevocable, other than as provided in Section 5(e). 

(b) Limitation on Payments. 

(i) In the event that the payments and benefits provided for in this Agreement or other payments and benefits payable or
provided to Executive (i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for this Section 6(b), would be subject to the excise tax imposed by Section 4999 of the Code,
then Executive’s payments and benefits under this Agreement or other payments or benefits (the “280G Amounts”) will be either: 

 (x) delivered in full, or 

(y) delivered as to such lesser extent which would result in no portion of such payments and benefits being subject to the
excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code, results in Executive’s
receipt on an after-tax basis, of the greatest amount of 280G Amounts, notwithstanding that all or some portion of the 280G Amounts may be taxable under Section 4999 of the Code. 

(ii) Reduction Order. In the event that a reduction of 280G Amounts is being made in accordance with this
Section 6(b), the reduction will occur, with respect to the 280G Amounts considered parachute payments within the meaning of Section 280G of the Code, in the following order: 

(1) reduction of cash payments in reverse chronological order (that is, the cash payment owed on the latest date following the
occurrence of the event triggering the excise tax will be the first cash payment to be reduced); 
 (2) cancellation of
equity awards that were granted “contingent on a change in ownership or control” within the meaning of Code Section 280G, or the vesting of which is based in whole or part on the attainment of performance goals, in the reverse order
of date of grant of the awards (that is, the most recently granted equity awards will be cancelled first); 
 (3) reduction
of the accelerated vesting of equity awards that vest solely based on continued employment, in the order of the portion of such awards that constitutes a parachute payment (that is, the awards the largest portion of which constitutes a parachute
payment will be reduced first); and 
 (4) reduction of employee benefits in reverse chronological order (that is, the
benefit owed on the latest date following the occurrence of the event triggering the excise tax will be the first benefit to be reduced). 

In no event will Executive have any discretion with respect to the ordering of payments or benefits. 

(iii) Firm. Unless the Company and Executive otherwise agree in writing, any determination required under this
Section 6(b) will be made in writing by a nationally recognized accounting or valuation firm (the “Firm”) selected by the Company, whose determination will be conclusive and binding upon Executive and the Company for all purposes. For
purposes of making the calculations required by this Section 6(b), the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of
Sections 280G and 4999 of the Code. The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section. The Company will bear all costs and make
all payments for the Firm’s services relating to any calculations contemplated by this Section 6(b). 
 (c)
Section 409A. 
 (i) Notwithstanding anything to the contrary in this Agreement, no severance pay
or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A of the Code, and
the final regulations and any guidance promulgated thereunder (“Section 409A”) (together, the “Deferred Compensation Separation Benefits”) will be paid or otherwise provided until Executive has a
“separation from service” within the meaning of Section 409A. 

 (ii) Any severance payments or benefits under this Agreement that would be
considered Deferred Compensation Severance Benefits will be paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following Executive’s separation from service. Any installment payments that would have been
made to Executive during the sixty (60) day period immediately following Executive’s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive’s separation from
service and the remaining payments shall be made as provided in this Agreement. 
 (iii) Notwithstanding anything to the
contrary in this Agreement, if Executive is a “specified employee” within the meaning of Section 409A at the time of Executive’s termination (other than due to death), then the Deferred Compensation Separation Benefits that are
payable within the first six (6) months following Executive’s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of
Executive’s separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the
contrary, if Executive dies following Executive’s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum
as soon as administratively practicable after the date of Executive’s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and
benefit payable under this Agreement, including the portion of the Executive’s Base Salary that is paid on each payroll date pursuant to Section 5(a)(i), is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 
 (iv) Any amount paid under
this Agreement that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation
Separation Benefits for purposes of clause (i) above. 
 (v) Any amount paid under this Agreement that qualifies as a
payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit (as defined below)
will not constitute Deferred Compensation Separation Benefits for purposes of clause (i) above. 
 (vi) The foregoing
provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities
herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of
any additional tax or income recognition prior to actual payment to Executive under Section 409A. In no event will the Company have any liability or obligation to reimburse, indemnify, or hold harmless Executive (or any other person) for any
taxes or costs that may be imposed on or incurred by Executive (or any other person) as a result of Section 409A. 
 (d)
Confidential Information Agreement. Executive’s receipt of any payments or benefits under Section 6 will be subject to Executive continuing to comply with the terms of Confidential Information Agreement (as defined in
Section 8). 

 (e) No Duty to Mitigate. Executive will not be required to mitigate the amount of any
payment contemplated by this Agreement, nor will any earnings that Executive may receive from any other source reduce any such payment. 

7. Definitions. 
 (a)
Cause. For purposes of this Agreement, “Cause” is defined as: (i) an act of dishonesty made by Executive in connection with Executive’s responsibilities as an employee that materially discredits, or is materially
detrimental to, the Company; (ii) Executive’s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude; (iii) a willful or reckless act made by Executive in
connection with Executive’s responsibilities as an employee that involves (A) physical violence or the threat of physical violence, (B) sexual harassment, (C) damage to property, and (D) the influence of alcohol or drugs;
(iv) Executive’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Executive owes an obligation of nondisclosure as a result of Executive’s relationship with the
Company; (v) Executive’s material breach of any obligations under any written agreement or covenant with the Company; or (vi) Executive’s willful, continued failure to perform Executive’s assigned employment duties after
Executive has received a written demand of performance from the Company with specifically sets forth the factual basis for the Company’s belief that Executive has not substantially performed Executive’s duties and has failed to cure such non-performance to the Company’s satisfaction within thirty (30) business days after receiving such notice. 

(b) Good Reason. For purposes of this Agreement, “Good Reason” means Executive’s resignation within thirty
(30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without Executive’s consent: (i) the assignment to Executive of any duties, or the reduction of
Executive’s duties, either of which results in a material diminution of Executive’s authority, duties, or responsibilities; (ii) the Board fails to appoint the Executive to the Board, or to nominate Executive for election or
reelection to the Board; (iii) a material reduction of Executive’s Base Salary (in other words, a reduction of more than 10% of Executive’s Base Salary in any one year, unless pursuant to a salary reduction program applicable
generally to the Company’s executives); (iv) a reduction of Executive’s Target Bonus; (v) the failure of the Company to obtain assumption of this Agreement by any acquirer or successor; or (vi) the failure of the Compensation
Committee to approve the Initial Option on the terms set forth in Section 3(a). Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for “Good
Reason” within ninety (90) days of the initial existence of the grounds for “Good Reason” and a reasonable cure period of not less than thirty (30) days following the date of such notice. Executive must resign effective not
later than sixty (60) days after the end of the Company cure period in the even such event(s), condition(s), or conduct is uncured. 

(c) Section 409A Limit. For purposes of this Agreement, “Section 409A Limit”
will mean two (2) times the lesser of: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Company’s taxable year preceding the Company’s taxable year of Executive’s
termination of employment as determined under Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be
taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Executive’s employment is terminated. 

8. Confidential Information; Restrictive Covenants. Executive agrees to enter into and abide by the Company’s standard
Confidential Information, Invention Assignment and Arbitration Agreement attached hereto as Exhibit A (the “Confidential Information Agreement”) entered into on or about the Effective Date. Executive acknowledges that such
Confidential Information Agreement will provider for, subject to the limits per applicable law, (i) a twelve (12) month non-competition provision applicable to Executive, (ii) a twelve
(12) month non-solicitation provision applicable to Executive, and (iii) a mutual non-disparagement provision. 

 9. Cooperation. The parties agree that certain matters in which the Executive will be
involved during the Employment Term may necessitate the Executive’s cooperation in the future. Accordingly, following the termination of the Executive’s employment for any reason, to the extent reasonably requested by the Company, the
Executive shall cooperate with the Company in connection with matters arising out of the Executive’s service to the Company; provided that, the Company shall make reasonable efforts to minimize disruption of the Executive’s other
activities. The Company shall reimburse the Executive for reasonable expenses incurred in connection with such cooperation. 
 10.
Representation of the Executive. The Executive represents and warrants to the Company that: 
 (a) The Executive is not, as of the
Effective Date, currently employed or engaged as an independent contractor with any other entity, and Executive’s acceptance of employment with the Company and the performance of his duties hereunder will not conflict with or result in a
violation of, a breach of, or a default under any contract, agreement or understanding to which he is a party or is otherwise bound. 
 (b)
The Executive’s acceptance of employment with the Company and the performance of his duties hereunder will not violate any non-solicitation, non-competition or
other similar covenant or agreement of a prior employer. 
 11. Assignment. This Agreement will be binding upon and inure to the
benefit of (a) the heirs, executors and legal representatives of Executive upon Executive’s death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of
this Agreement for all purposes. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or
substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution.
Any other attempted assignment, transfer, conveyance or other disposition of Executive’s right to compensation or other benefits will be null and void. 

12. Notices. All notices, requests, demands and other communications called for hereunder will be in writing and will be deemed given
(i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well-established commercial overnight service, or (iii) four (4) days after being mailed by registered or certified mail, return receipt
requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing: 

If to the Company: 

Viracta Therapeutics, Inc. 

2533 S. Coast Hwy. 101, Suite 210 

Cardiff, California 

Attn: Chairman of the Board of Directors 

If to Executive: 

at the last residential address known by the Company. 

 13. Severability. In the event that any provision hereof becomes or is declared by a
court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision. The parties further agree that any such court is expressly authorized to modify any such
unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language
to this Agreement or by making such other modifications as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. The parties expressly agree that this Agreement as so
modified by the court shall be binding upon and enforceable against each of them. 
 14. Professional Fees. Company will reimburse
Executive’s reasonable attorneys’ fees relating to the negotiation and preparation of this Agreement and any other agreement relating to Executive joining the Company not to exceed $15,000 in the aggregate. 

15. Arbitration. Executive agrees that any and all controversies, claims, or disputes with anyone (including the Company and any
employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive’s service to the Company, will be subject to arbitration in accordance with
the provisions of the Confidential Information Agreement. 
 16. Integration. This Agreement, together with the Option Plan, option
agreement thereunder, the Confidential Information Agreement, and the Indemnification Agreement (as defined in Section 23) represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all
prior or contemporaneous agreements whether written or oral. This Agreement may be modified only by agreement of the parties by a written instrument executed by the parties that is designated as an amendment to this Agreement. 

17. Modification: Waiver of Breach. No provision of this Agreement may be amended or modified unless such amendment or modification is
agreed to in writing and signed by the Executive and by the Board or its designee. The waiver of a breach of any term or provision of this Agreement, which must be in writing, will not operate as or be construed to be a waiver of any other previous
or subsequent breach of this Agreement. 
 18. Headings. All captions and section headings used in this Agreement are for convenient
reference only and do not form a part of this Agreement. 
 19. Tax Withholding. All payments made pursuant to this Agreement will be
subject to withholding of applicable taxes. 
 20. Governing Law. This Agreement will be governed by the laws of the State of New
Hampshire (with the exception of its conflict of laws provisions). 
 21. Acknowledgment. Executive acknowledges that Executive has
had the opportunity to discuss this matter with and obtain advice from Executive’s private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily
entering into this Agreement. 
 22. Counterparts. This Agreement may be executed in counterparts, and each counterpart will have the
same force and effect as an original and will constitute an effective, binding agreement on the part of each of the undersigned. 
 23.
Indemnification Agreement. The parties shall enter into an indemnification agreement in the form attached hereto as Exhibit B (the “Indemnification Agreement”). 

 24. Survival. The provisions of this Agreement shall survive the termination of the
Agreement, and of the Employment Period for any reason, to the extent necessary to enable the parties to enforce their respective rights hereunder. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement (in the case of the
Company, by a duly authorized officer or director), effective as of the Effective Date. 
  

									
	 COMPANY:
	 		 		 	
				
	 VIRACTA THERAPEUTICS, INC.
	 		 		 	
				
	 By:
	 	 /s/ Roger J. Pomerantz, M.D.
	 		 	 Date: September 15, 2022

	 Name: Roger J. Pomerantz, M.D.
	 		 		 	
	 Title: Chairman of the Board
	 	
                       
 
	 	         
	 	
				
	 EXECUTIVE:
	 		 		 	
				
	 MARK ROTHERA
	 		 		 	
			
	 /s/ Mark Rothera
	 		 	 Date: September 15, 2022

 [SIGNATURE PAGE TO EMPLOYMENT AGREEMENT] 

 EXHIBIT A 

CONFIDENTIAL INFORMATION AGREEMENT 

 VIRACTA THERAPEUTICS, INC. 

CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT AND ARBITRATION AGREEMENT 

As a condition of my employment with Viracta Therapeutics, Inc. (the “Company”), and in consideration of my
employment with the Company and my receipt of the compensation now and hereafter paid to me by the Company, I agree to the following provisions of this Confidential Information, Invention Assignment and Arbitration Agreement
(this “Agreement”): 
 1.
AT-WILL EMPLOYMENT 

I UNDERSTAND AND ACKNOWLEDGE THAT MY EMPLOYMENT WITH THE COMPANY IS FOR NO SPECIFIED TERM AND CONSTITUTES “AT-WILL” EMPLOYMENT. I ALSO UNDERSTAND THAT ANY REPRESENTATION TO THE CONTRARY IS UNAUTHORIZED AND NOT VALID UNLESS IN WRITING AND SIGNED BY THE PRESIDENT OR CEO OF THE COMPANY. ACCORDINGLY, I ACKNOWLEDGE
THAT MY EMPLOYMENT RELATIONSHIP MAY BE TERMINATED AT ANY TIME, WITH OR WITHOUT GOOD CAUSE OR FOR ANY OR NO CAUSE, AT MY OPTION OR AT THE OPTION OF THE COMPANY, WITH OR WITHOUT NOTICE. I FURTHER ACKNOWLEDGE THAT THE COMPANY MAY MODIFY JOB TITLES,
SALARIES, AND BENEFITS FROM TIME TO TIME AS IT DEEMS NECESSARY. 
 2.
CONFIDENTIALITY 
 A. Definition of Company Confidential Information.
“Company Confidential Information” means information (including any and all combinations of individual items of information) that the Company has or will develop, acquire, create, compile, discover or own, that has value in or to
the Company’s business which is not generally known and which the Company wishes to maintain as confidential. Company Confidential Information includes both (i) information created by others that I learn or that becomes available to me
through the Company or its agents; and (ii) information I create that the Company owns pursuant to Section 3 of this Agreement. By way of example, and without limitation, Company Confidential Information includes any and all non-public information that relates to the actual or anticipated business and/or products, research or development of the Company, or to the Company’s technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or other information regarding the Company’s products or services and markets therefor, customer lists and customers (including, but not limited
to, customers of the Company on which I called or with which I may become acquainted during the term of my employment), software, developments, inventions, discoveries, ideas, processes, formulas, technology, designs, drawings, engineering, hardware
configuration information, marketing, finances, and other business information disclosed by the Company either directly or indirectly in writing, orally or by drawings or inspection of premises, parts, equipment, or other Company property.
Notwithstanding the foregoing, Company Confidential Information does not include general knowledge, skill, and experience I have acquired during the course of or in connection with my employment with the Company or a former employer. In addition,
Company Confidential Information shall not include any such information which I can establish (i) was publicly known or made generally available prior to the time of disclosure by the Company to me; (ii) becomes publicly known or made
generally available after disclosure by the Company to me through no wrongful action or omission by me; or (iii) is in my rightful possession, without confidentiality obligations, at the time of disclosure by the Company as shown by my
then-contemporaneous written records; provided that any combination of individual items of information shall not be deemed to be within any of the foregoing exceptions merely because one or more of the individual items are within such exception,
unless the combination as a whole is within such exception. 
 B. Nonuse and Nondisclosure. During and after my
employment with the Company, I will hold in the strictest confidence and take all reasonable precautions to prevent any unauthorized use or disclosure of Company Confidential Information. I will not (i) use Company Confidential Information for
any purpose whatsoever other than for the benefit of the Company in the course of my employment, or (ii) disclose Company Confidential Information to any third party without the prior written authorization of the President, CEO, or the Board of
Directors of the Company. Prior to disclosure, when compelled by applicable law, I shall provide prior written notice to the President, CEO, and General Counsel of the Company (as applicable). I agree that I obtain no title to any Company
Confidential Information, and that the Company retains all Confidential Information as the sole property of the Company. I understand that my unauthorized use or disclosure of Company Confidential Information during my employment may lead to
disciplinary action, up to and including, immediate termination and legal action by the Company. I understand that my obligations under this section shall continue after termination of my employment and also that nothing in this Agreement prevents
me from engaging in protected conduct, as described in the Protected Activity Not Prohibited section below. 

 C. Former Employer Confidential Information. I agree that during my
employment with the Company, I will not improperly use, disclose, or induce the Company to use any proprietary information or trade secrets of any former employer or other person or entity with which I have an obligation to keep such proprietary
information or trade secrets in confidence. I further agree that I will not bring onto the Company’s premises or transfer onto the Company’s technology systems any unpublished document, proprietary information, or trade secrets belonging
to any such third party unless disclosure to, and use by, the Company has been consented to, in writing, by such third party and the Company. 

D. Third Party Information. I recognize that the Company has received, and in the future may receive, from third parties
(for example, customers, suppliers, licensors, licensees, partners, and collaborators) as well as its subsidiaries and affiliates (“Associated Third Parties”), information which the Company is required to maintain and treat as
confidential or proprietary information of such Associated Third Parties (“Associated Third Party Confidential Information”), and I agree to use such Associated Third Party Confidential Information only as directed by the Company
and to not use or disclose such Associated Third Party Confidential Information in a manner that would violate the Company’s obligations to such Associated Third Parties. By way of example, Associated Third Party Confidential Information may
include the habits or practices of Associated Third Parties, the technology of Associated Third Parties, requirements of Associated Third Parties, and information related to the business conducted between the Company and such Associated Third
Parties. I agree at all times during my employment with the Company and thereafter, that I owe the Company and its Associated Third Parties a duty to hold all such Associated Third Party Confidential Information in the strictest confidence, and not
to use it or to disclose it to any person, firm, corporation, or other third party except as necessary in carrying out my work for the Company consistent with the Company’s agreement with such Associated Third Parties. I further agree to comply
with any and all Company policies and guidelines that may be adopted from time to time regarding Associated Third Parties and Associated Third Party Confidential Information. I understand that my unauthorized use or disclosure of Associated Third
Party Confidential Information or violation of any Company policies during my employment may lead to disciplinary action, up to and including, immediate termination and legal action by the Company. 

3. OWNERSHIP 

A. Assignment of Inventions. As between the Company and myself, I agree that all right, title, and interest in and to
any and all copyrightable material, notes, records, drawings, designs, logos, inventions, improvements, developments, discoveries, ideas and trade secrets conceived, discovered, authored, invented, developed or reduced to practice by me, solely or
in collaboration with others, during the period of time I am in the employ of the Company (including during my off-duty hours), or with the use of the Company’s equipment, supplies, facilities, or Company
Confidential Information, and any copyrights, patents, trade secrets, mask work rights or other intellectual property rights relating to the foregoing, except as provided in Section 3.G below (collectively,
“Inventions”), are the sole property of the Company. I also agree to promptly make full written disclosure to the Company of any Inventions, and to deliver and assign and hereby irrevocably assign fully to the Company all of my
right, title and interest in and to Inventions. I agree that this assignment includes a present conveyance to the Company of ownership of Inventions that are not yet in existence. I further acknowledge that all original works of authorship that are
made by me (solely or jointly with others) within the scope of and during the period of my employment with the Company and that are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright
Act. I understand and agree that the decision whether or not to commercialize or market any Inventions is within the Company’s sole discretion and for the Company’s sole benefit, and that no royalty or other consideration will be due to me
as a result of the Company’s efforts to commercialize or market any such Inventions. 
 B. Pre-Existing Materials. I will inform the Company, in writing, before incorporating any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade secrets and other
proprietary information or intellectual property rights owned by me or in which I have an interest prior to, or separate from, my employment with the Company, including, without limitation, any such inventions that meet the criteria set forth herein
under Section 3.G, (“Prior Inventions”) into any Invention or otherwise utilizing any Prior Invention in the course of my 

  
 Page 2 of 15 

 
employment with the Company; and the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable worldwide license (with the right to grant and authorize
sublicenses) to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such incorporated or utilized Prior Inventions, without restriction,
including, without limitation, as part of or in connection with such Invention, and to practice any method related thereto. I will not incorporate any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade
secrets and other proprietary information or intellectual property rights owned by any third party into any Invention without the Company’s prior written permission. I have attached hereto, as Exhibit A a list describing all Prior
Inventions that relate to the Company’s current or anticipated business, products, or research and development or, if no such list is attached, I represent and warrant that there are no such Prior Inventions. Furthermore, I represent and
warrant that if any Prior Inventions are included on Exhibit A, they will not materially affect my ability to perform all obligations under this Agreement. 

C. Moral Rights. Any assignment to the Company of Inventions includes all rights of attribution, paternity, integrity,
modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like (collectively, “Moral
Rights”). To the extent that Moral Rights cannot be assigned under applicable law, I hereby waive and agree not to enforce any and all Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent
permitted under applicable law. 
 D. Maintenance of Records. I agree to keep and maintain adequate, current,
accurate, and authentic written records of all Inventions made by me (solely or jointly with others) during the term of my employment with the Company. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any
other format that may be specified by the Company. As between the Company and myself, the records are and will be available to and remain the sole property of the Company at all times. 

E. Further Assurances. I agree to assist the Company, or its designee, at the Company’s expense, in every proper
way to secure the Company’s rights in the Inventions in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths,
assignments, and all other instruments that the Company shall deem proper or necessary in order to apply for, register, obtain, maintain, defend, and enforce such rights, and in order to deliver, assign and convey to the Company, its successors,
assigns, and nominees the sole and exclusive rights, title, and interest in and to all Inventions, and testifying in a suit or other proceeding relating to such Inventions. I further agree that my obligations under this Section 3.E shall
continue after the termination of this Agreement. 
 F.
Attorney-in-Fact. I agree that, if the Company is unable because of my unavailability, mental or physical incapacity, or for any other reason to secure my
signature with respect to any Inventions, including, without limitation, for the purpose of applying for or pursuing any application for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to
the Company in Section 3.A, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and
attorney-in-fact, to act for and on my behalf to execute and file any papers and oaths, and to do all other lawfully permitted acts with respect to such Inventions to
further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by me. This power of attorney shall be deemed coupled with an interest, and shall be irrevocable. 

G. Exception to Assignments. I UNDERSTAND THAT THE PROVISIONS OF THIS AGREEMENT REQUIRING ASSIGNMENT OF INVENTIONS (AS
DEFINED UNDER SECTION 3.A ABOVE) TO THE COMPANY DO NOT APPLY TO ANY INVENTION FOR WHICH NO EQUIPMENT SUPPLIES, FACILITY, OR TRADE SECRET INFORMATION OF THE COMPANY WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON MY OWN TIME (AN “OTHER
INVENTION”) EXCEPT FOR THOSE OTHER INVENTIONS THAT RELATE: (A) DIRECTLY TO THE BUSINESS OF THE COMPANY; (B) TO THE COMPANY’S ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT; OR (C) RESULT FROM ANY WORK I
PERFORM FOR THE COMPANY. I WILL NOT INCORPORATE, OR PERMIT TO BE INCORPORATED, ANY OTHER INVENTION OWNED BY ME OR IN WHICH I HAVE AN INTEREST INTO A COMPANY PRODUCT, PROCESS OR SERVICE WITHOUT THE COMPANY’S PRIOR WRITTEN CONSENT. I WILL ADVISE
THE COMPANY PROMPTLY IN WRITING OF ANY INVENTIONS THAT I BELIEVE MEET THE ABOVE CRITERIA AND ARE NOT OTHERWISE DISCLOSED ON EXHIBIT A TO PERMIT A DETERMINATION OF OWNERSHIP BY THE COMPANY. ANY SUCH DISCLOSURE WILL BE RECEIVED IN CONFIDENCE.

  
 Page 3 of 15 

 4. CONFLICTING
OBLIGATIONS 
 A. Current Obligations. I agree that during the term of my
employment with the Company, I will not engage in or undertake any other employment, occupation, consulting relationship, or commitment that is directly related to the business in which the Company is now involved or becomes involved or has plans to
become involved, nor will I engage in any other activities that conflict with my obligations to the Company. 
 B. Prior
Relationships. Without limiting Section 4.A, I represent and warrant that I have no other agreements, relationships, or commitments to any other person or entity that conflict with the provisions of this Agreement, my obligations to the
Company under this Agreement, or my ability to become employed and perform the services for which I am being hired by the Company. I further agree that if I have signed a confidentiality agreement or similar type of agreement with any former
employer or other entity, I will comply with the terms of any such agreement to the extent that its terms are lawful under applicable law. I represent and warrant that after undertaking a careful search (including searches of my computers, cell
phones, electronic devices, and documents), I have returned all property and confidential information belonging to all prior employers (and/or other third parties I have performed services for in accordance with the terms of my applicable
agreement). Moreover, I agree to fully indemnify the Company, its directors, officers, agents, employees, investors, shareholders, administrators, affiliates, divisions, subsidiaries, predecessor and successor corporations, and assigns for all
verdicts, judgments, settlements, and other losses incurred by any of them resulting from my breach of my obligations under any agreement with a third party to which I am a party or obligation to which I am bound, as well as any reasonable
attorneys’ fees and costs if the plaintiff is the prevailing party in such an action, except as prohibited by law. 

5. RETURN OF COMPANY MATERIALS

 A. Definition of Electronic Media Equipment and Electronic Media Systems. “Electronic Media
Equipment” includes, but is not limited to, computers, external storage devices, thumb drives, mobile devices (including, but not limited to, smart phones, tablets, and e-readers), telephone
equipment, and other electronic media devices. “Electronic Media Systems” includes, but is not limited to, computer servers, messaging and email systems or accounts, applications for computers or mobile devices, and web-based services (including cloud-based information storage accounts). 
 B. Return of
Company Property. I understand that anything that I created or worked on for the Company while working for the Company belongs solely to the Company and that I cannot remove, retain, or use such information without the Company’s express
written permission. Accordingly, upon separation from employment with the Company or upon the Company’s request at any other time, I will immediately deliver to the Company, and will not keep in my possession (or custody or control), recreate,
or deliver to anyone else, any and all Company property, including, but not limited to, Company Confidential Information, Associated Third Party Confidential Information, all Company equipment including all Electronic Media Equipment that was
provided to me by or that I used on behalf of the Company, all tangible embodiments of the Inventions, all electronically stored information and passwords to access such information, Company credit cards, records, data, notes, notebooks, reports,
files, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, photographs, charts, any other documents and property, and reproductions of any of the foregoing items including, without limitation, those records
maintained pursuant to Section 3.D. Notwithstanding the foregoing, I understand that I am allowed to keep a copy of the Company’s employee handbook and personnel records relating to my employment. 

C. Return of Company Information on Company Electronic Media Equipment. In connection with my obligation to return
information to the Company, I agree that I will not copy, delete, or alter any information, including personal information voluntarily created or stored, contained in Company Electronic Media Equipment before I return the information or property to
the Company. 

  
 Page 4 of 15 

 D. Return of Company Information on Personal Electronic Media Equipment
or Personal Electronic Media Systems. If I have used any personal Electronic Media Equipment or personal Electronic Media Systems to create, receive, store, review, prepare, or transmit any Company information, including, but not limited to,
Company Confidential Information, I agree to make a prompt and reasonable search for such information in good faith, including reviewing any personal Electronic Media Equipment or personal Electronic Media Systems to locate such information and, if
I locate such information, I agree to notify the Company of that fact and then provide the Company with a computer-useable copy of all such Company information from those equipment and systems. I agree to cooperate reasonably with the Company to
verify that the necessary copying is completed (including upon request providing a sworn declaration confirming the return of property and deletion of information), and, upon confirmation of compliance by the Company, I agree to delete and expunge
all Company information. 
 E. No Expectation of Privacy in Company Property. I understand that I have no expectation
of privacy in Company property, and I agree that any Company property is subject to inspection by Company personnel at any time with or without further notice. As to any personal Electronic Media Equipment or personal Electronic Media Systems that I
have used for Company purposes, I agree that the Company, at its sole discretion, may have reasonable access, as determined by the Company in good faith, to such personal Electronic Media Equipment or personal Electronic Media Systems to review,
retrieve, destroy, or ensure the permanent deletion of Company information from such equipment or systems or to take such other actions necessary to protect the Company or Company property, as determined by the Company reasonably and in good faith.
I also consent to an exit interview and an audit to confirm my compliance with this Section 5, and I will certify in writing that I have complied with the requirements of this Section 5. 

6. TERMINATION CERTIFICATION 

Upon separation from employment with the Company, I agree to immediately sign and deliver to the Company the “Termination
Certification” attached hereto as Exhibit C. 
 7. NOTIFICATION OF
NEW EMPLOYER 
 In the event that I leave the employ of the Company, I
hereby grant consent to notification by the Company to my new employer about my obligations under this Agreement. I also agree to keep the Company advised of my home and business address for a period of three (3) years after termination of my
employment with the Company, so that the Company can contact me regarding my continuing obligations provided by this Agreement. 

8. COVENANT NOT TO COMPETE AND
NO SOLICITATION 
 A. Covenant Not to Compete. I agree that
during the course of my employment, and for a period of twelve (12) months immediately following the termination of my relationship with the Company if I resign voluntarily without Good Reason or if I am terminated by the Company involuntarily
with Cause, I will not, without the prior written consent of the Company, whether paid or not: (i) serve as a partner, principal, licensor, licensee, employee, consultant, officer, director, manager, agent, representative, advisor, promoter,
associate, investor, or otherwise for (except for passive ownership of one percent (1%) or less of any entity whose securities have been registered under the Securities Act of 1933, as amended, or Section 12 of the Securities Exchange Act of
1934, as amended); (ii) directly or indirectly, own, purchase, organize or take preparatory steps for the organization of; or (iii) build, design, finance, acquire, lease, operate, manage, control, invest in, work or consult for or otherwise
join, participate in any business whose business, products or operations are in any respect involved in the Covered Business. For purposes of this Agreement, “Covered Business” shall mean any business in which the Company is
engaged or in which the Company has plans to be engaged, or any service that the Company provides or has plans to provide. The foregoing covenant shall cover my activities in every part of the Territory. “Territory” shall mean
(i) all counties in the State of New Hampshire; (ii) all other states of the United States of America in which the Company provided goods or services, had customers, or otherwise conducted business at any time during the two-year period prior to the date of the termination of my relationship with the Company; and (iii) any other countries from which the Company provided goods or services, had customers, or otherwise conducted
business at any time during the two-year period prior to the date of the termination of my relationship with the Company. Should I obtain other employment during my employment with the Company, or within
twelve (12) months immediately following the termination of my relationship with the Company if this Section 8.A is in effect, I agree to provide written notification to the Company as to the name and address of my new employer, the
position that I expect to hold, and a general description of my duties and responsibilities, at least three (3) business days prior to starting such employment. 

  
 Page 5 of 15 

 B. No Solicitation.  

(1) Non-Solicitation of Customers. I agree that for a period of twelve
(12) months immediately following the termination of my relationship with the Company, whether I resign voluntarily or am terminated by the Company involuntarily, I shall not contact, or cause to be contacted, directly or indirectly, or engage
in any form of oral, verbal, written, recorded, transcribed, or electronic communication with any Customer for the purposes of conducting business that is competitive or similar to that of the Company or for the purpose of disadvantaging the
Company’s business in any way. For purposes of foregoing, “Customer” means all persons or entities that have purchased, used or inquired of the Company’s products or services at any time during the two-year period preceding the termination of my employment with the Company and with whom I had material contact during such period. For purposes of the foregoing, “material contact” means
(A) I dealt with such Customer on behalf of the Company; (B) such Customer’s dealings with the Company were coordinated or supervised by me, in whole or in part; or (C) I obtained confidential information regarding such Customer,
including, without limitation any Company Confidential Information or Associated Third-Party Confidential Information. I acknowledge and agree that the Customers did not use or inquire of the Company’s services solely as a result of my efforts,
and that the efforts of other Company personnel and resources are responsible for the Company’s relationship with the Customers. I further acknowledge and agree that the identity of the Customers is not readily ascertainable or discoverable
through public sources, and that the Company’s list of Customers was cultivated with great effort and secured through the expenditure of considerable time and money by the Company. 

(2) Non-Solicitation of Employees. I agree that for a period of twelve
(12) months immediately following the termination of my relationship with the Company, whether I resign voluntarily or am terminated by the Company involuntarily, I will not directly or indirectly hire, solicit, or recruit, or attempt to hire,
solicit, or recruit, any employee of the Company to leave their employment with the Company, nor will I contact any employee of the Company, or cause an employee of the Company to be contacted, for the purpose of leaving employment with the Company.
For purposes of the foregoing, the term “employee” shall be limited to those employees with whom I interacted during the last two (2) years of my employment with the Company or about whom I obtained personnel information or
other Company Confidential Information about such employee as a result of my position with the Company during the last two (2) years of my employment with the Company. 

(3) Non-Solicitation of Others. I agree that for a period of twelve
(12) months immediately following the termination of my relationship with the Company, whether I resign voluntarily or am terminated by the Company involuntarily, I will not solicit, encourage, or induce, or cause to be solicited, encouraged or
induced, directly or indirectly, any Business Partner to terminate or adversely modify any business relationship with the Company or not to proceed with, or enter into, any business relationship with the Company, nor shall I otherwise interfere with
any business relationship between the Company and any Business Partner. For purposes of the foregoing, “Business Partner” means any business partner, franchisee, joint venture, supplier, vendor or contractor who conducted business
with the Company at any time during the two-year period preceding the termination of my employment with the Company and with whom I had material contact during such period. For purposes of the foregoing,
“material contact” means (A) I dealt with such Business Partner on behalf of the Company; (B) such Business Partner’s dealings with the Company were coordinated or supervised by me, in whole or in part; or (C) I
obtained confidential information regarding such Business Partner, including, without limitation, Company Confidential Information or Associated Third-Party Confidential Information. 

C. Acknowledgements. I acknowledge that I will derive significant value from the Company’s agreement to provide me
with Company Confidential Information to enable me to optimize the performance of my duties to the Company. I further acknowledge that my fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation
neither to disclose nor to use Company Confidential Information other than for the Company’s exclusive benefit and my obligations not to compete and not to solicit contained in subsections (A) and (B) above, is necessary to protect Company
Confidential Information and, consequently, to preserve the value and goodwill of the Company. I also acknowledge the time, geographic and scope limitations of my obligations under subsections (A) and (B) above are fair and reasonable in
all respects, especially in light of the Company’s need to protect Company Confidential Information and the scope and nature of the Company’s business, and that I will not be precluded from gainful employment if I am obligated not to
compete with the Company or solicit its customers, employees, or others during the period and 

  
 Page 6 of 15 

 
within the Territory as described above. In the event of my breach or violation of this Section 8, or good faith allegation by the Company of my breach or violation of
this Section 8, to the maximum extent permitted by law the restricted periods set forth in this Section 8 shall be tolled until such breach or violation, or dispute related to an allegation by the
Company that I have breached or violated this Section 8, has been duly cured or resolved, as applicable. I agree that nothing in this Section 8 shall affect my continuing obligations under this
Agreement during and after this twelve (12) month period, including, without limitation, my obligations under Section 2. 

D. Separate Covenants. The covenants contained in subsections (A) and (B) above shall be construed as a
series of separate covenants, one for each city, county and state of any geographic area in the Territory. Except for geographic coverage, each such separate covenant shall be deemed identical in terms to the covenant contained in subsections
(A) and (B) above. If, in any judicial or arbitral proceeding, a court or arbitrator refuses to enforce any of such separate covenants (or any part thereof), then such unenforceable covenant (or such part) shall be revised, or if revision
is not permitted it shall be eliminated from this Agreement, to the extent necessary to permit the remaining separate covenants (or portions thereof) to be enforced. In the event that the provisions of subsections (A) and (B) above are
deemed to exceed the time, geographic or scope limitations permitted by applicable law, then such provisions shall be reformed to the maximum time, geographic or scope limitations, as the case may be, then permitted by such law. In the event that
the applicable court or arbitrator does not exercise the power granted to it in the prior sentence, I and the Company agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve,
to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.  
 9.
CONFLICT OF INTEREST GUIDELINES 
 I
agree to diligently adhere to all policies of the Company, including the Company’s insider trading policies and the Company’s Conflict of Interest Guidelines. A copy of the Company’s current Conflict of Interest Guidelines is attached
as Exhibit D hereto, but I understand that these Conflict of Interest Guidelines may be revised from time to time during my employment. 

10. REPRESENTATIONS 

Without limiting my obligations under Section 3.E above, I agree to execute any proper oath or verify any proper document
required to carry out the terms of this Agreement. I represent and warrant that my performance of all the terms of this Agreement will not breach any agreement to maintain the confidentiality of information acquired by me in confidence or in trust
prior to my employment by the Company. I hereby represent and warrant that I have not entered into, and I will not enter into, any oral or written agreement in conflict herewith. 

11. AUDIT 

I acknowledge that I have no reasonable expectation of privacy in any Company Electronic Media Equipment or Company Electronic
Media Systems. All information, data, and messages created, received, sent, or stored in Company Electronic Media Equipment or Company Electronic Media Systems are, at all times, the property of the Company. As such, the Company has the right to
audit and search all such items and systems, without further notice to me, to ensure that the Company is licensed to use the software on the Company’s devices in compliance with the Company’s software licensing policies, to ensure
compliance with the Company’s policies, and for any other business-related purposes in the Company’s sole discretion. I understand that I am not permitted to add any unlicensed, unauthorized, or
non-compliant applications to the Company’s technology systems, including, without limitation, open source or free software not authorized by the Company, and that I shall refrain from copying unlicensed
software onto the Company’s technology systems or using non-licensed software or websites. I understand that it is my responsibility to comply with the Company’s policies governing use of the
Company’s documents and the internet, email, telephone, and technology systems to which I will have access in connection with my employment. In addition, as to any personal Electronic Media Equipment or personal Electronic Media Systems or
other personal property that I have used for Company purposes, I agree that the Company may have reasonable access to such personal Electronic Media Equipment or personal Electronic Media Systems or other personal property to review, retrieve,
destroy, or ensure the permanent deletion of Company information from such equipment or systems or property or take such other actions that are needed to protect the Company or Company property, as determined by the Company reasonably and in good
faith. 

  
 Page 7 of 15 

 I am aware that the Company has or may acquire software and systems that are
capable of monitoring and recording all Company network traffic to and from any Company Electronic Media Equipment or Company Electronic Media Systems. The Company reserves the right to access, review, copy, and delete any of the information, data,
or messages accessed through Company Electronic Media Equipment or Company Electronic Media Systems, with or without notice to me and/or in my absence. This includes, but is not limited to, all e-mail messages
sent or received, all website visits, all chat sessions, all news group activity (including groups visited, messages read, and postings by me), and all file transfers into and out of the Company’s internal networks. The Company further reserves
the right to retrieve previously deleted messages from e-mail or voicemail and monitor usage of the Internet, including websites visited and any information I have downloaded. In addition, the Company may
review Internet and technology systems activity and analyze usage patterns, and may choose to publicize this data to assure that technology systems are devoted to legitimate business purposes. 

12. ARBITRATION AND EQUITABLE RELIEF  

A. Arbitration. IN CONSIDERATION OF MY EMPLOYMENT WITH THE COMPANY, THE COMPANY’S PROMISE TO ARBITRATE ALL
EMPLOYMENT-RELATED DISPUTES WITH ME, AND MY RECEIPT OF COMPENSATION AND OTHER BENEFITS PAID OR PROVIDED TO ME BY THE COMPANY AT PRESENT AND IN THE FUTURE, I AGREE THAT ANY AND ALL CONTROVERSIES, CLAIMS, OR DISPUTES THAT I MAY HAVE WITH THE COMPANY
(INCLUDING ANY COMPANY EMPLOYEE, OFFICER, DIRECTOR, TRUSTEE, OR BENEFIT PLAN OF THE COMPANY, IN THEIR CAPACITY AS SUCH OR OTHERWISE), ARISING OUT OF, RELATING TO, OR RESULTING FROM MY EMPLOYMENT OR RELATIONSHIP WITH THE COMPANY OR THE TERMINATION OF
MY EMPLOYMENT OR RELATIONSHIP WITH THE COMPANY, INCLUDING ANY BREACH OF THIS AGREEMENT, SHALL BE SUBJECT TO BINDING ARBITRATION PURSUANT TO THE FEDERAL ARBITRATION ACT (9 U.S.C. SEC. 1 ET SEQ.) (THE “FAA”). THE FAA’S
SUBSTANTIVE AND PROCEDURAL PROVISIONS SHALL EXCLUSIVELY GOVERN AND APPLY WITH FULL FORCE AND EFFECT TO THIS ARBITRATION AGREEMENT, INCLUDING ITS ENFORCEMENT. ANY STATE COURT OF COMPETENT JURISDICTION SHALL STAY PROCEEDINGS PENDING ARBITRATION OR
COMPEL ARBITRATION IN THE SAME MANNER AS A FEDERAL COURT UNDER THE FAA. I FURTHER AGREE THAT, TO THE FULLEST EXTENT PERMITTED BY LAW, I MAY BRING ANY ARBITRATION PROCEEDING ONLY IN MY INDIVIDUAL CAPACITY, AND NOT AS A PLAINTIFF, REPRESENTATIVE, OR
CLASS MEMBER IN ANY PURPORTED CLASS, COLLECTIVE, OR REPRESENTATIVE LAWSUIT OR PROCEEDING. I AGREE TO ARBITRATE ANY AND ALL COMMON LAW AND/OR STATUTORY CLAIMS UNDER LOCAL, STATE, OR FEDERAL LAW, INCLUDING, BUT NOT LIMITED TO, CLAIMS UNDER THE NEW
HAMPSHIRE LAW AGAINST DISCRIMINATION; THE NEW HAMPSHIRE CIVIL RIGHTS ACT; TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, THE AMERICANS WITH DISABILITIES ACT OF 1990, THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, THE OLDER WORKERS BENEFIT PROTECTION
ACT, THE WORKER ADJUSTMENT AND RETRAINING NOTIFICATION ACT, THE FAIR LABOR STANDARDS ACT, THE FAIR CREDIT REPORTING ACT, THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AND THE FAMILY AND MEDICAL LEAVE ACT, CLAIMS RELATING TO EMPLOYMENT STATUS,
COMPENSATION (CASH, EQUITY, BONUS, OR OTHERWISE), OR CLASSIFICATION, AND CLAIMS OF HARASSMENT, DISCRIMINATION, RETALIATION, WRONGFUL TERMINATION, AND BREACH OF CONTRACT, EXCEPT AS PROHIBITED BY LAW. TO THE FULLEST EXTENT PERMITTED BY LAW, I
ALSO AGREE TO ARBITRATE ANY AND ALL DISPUTES ARISING OUT OF OR RELATING TO THE INTERPRETATION OR APPLICATION OF THIS AGREEMENT TO ARBITRATE, BUT NOT DISPUTES ABOUT THE ENFORCEABILITY, REVOCABILITY OR VALIDITY OF THIS AGREEMENT TO ARBITRATE OR
THE CLASS, COLLECTIVE, AND REPRESENTATIVE PROCEEDING WAIVER HEREIN. WITH RESPECT TO ALL SUCH CLAIMS AND DISPUTES THAT I AGREE TO ARBITRATE, I HEREBY EXPRESSLY AGREE TO WAIVE, AND DO WAIVE, ANY RIGHT TO A TRIAL BY JURY. I FURTHER
UNDERSTAND THAT THIS AGREEMENT TO ARBITRATE ALSO APPLIES TO ANY DISPUTES THAT THE COMPANY MAY HAVE WITH ME. I UNDERSTAND THAT NOTHING IN THIS AGREEMENT REQUIRES ME TO ARBITRATE CLAIMS THAT CANNOT BE ARBITRATED UNDER APPLICABLE LAW, SUCH AS THE
SARBANES-OXLEY ACT. 

  
 Page 8 of 15 

 B. Administration of Arbitration. I AGREE THAT ANY ARBITRATION WILL
BE ADMINISTERED BY JAMS, PURSUANT TO ITS EMPLOYMENT ARBITRATION RULES & PROCEDURES (THE “JAMS EMPLOYMENT RULES”), WHICH ARE AVAILABLE AT http://www.jamsadr.com/rules-employment-arbitration/ AND FROM THE COMPANY. IF THE JAMS
EMPLOYMENT RULES CANNOT BE ENFORCED AS TO THE ARBITRATION, THEN THE PARTIES AGREE THAT THEY WILL ARBITRATE THIS DISPUTE UTILIZING THE JAMS COMPREHENSIVE ARBITRATION RULES AND PROCEDURES OR SUCH RULES AS THE ARBITRATOR MAY DEEM MOST APPROPRIATE FOR
THE DISPUTE (THE RULES UNDER WHICH THE ARBITRATION IS ADMINISTERED, WHETHER THE JAMS EMPLOYMENT RULES OR OTHERWISE, ARE REFERRED TO HEREIN AS THE “JAMS RULES”). IN THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF THIS SECTION 12
AND THE JAMS RULES, THIS SECTION 12 SHALL TAKE PRECEDENCE. I AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO DECIDE ANY MOTIONS BROUGHT BY ANY PARTY TO THE ARBITRATION, INCLUDING MOTIONS FOR SUMMARY JUDGMENT AND/OR ADJUDICATION, AND
MOTIONS TO DISMISS, APPLYING THE STANDARDS SET FORTH FOR SUCH MOTIONS UNDER APPLICABLE NEW HAMPSHIRE LAW, INCLUDING THE NEW HAMPSHIRE CIVIL PROCEDURE RULES. I AGREE THAT THE ARBITRATOR SHALL ISSUE A WRITTEN DECISION ON THE MERITS. I ALSO AGREE THAT
THE ARBITRATOR SHALL HAVE THE POWER TO AWARD ANY REMEDIES AVAILABLE UNDER APPLICABLE LAW, AND THAT THE ARBITRATOR MAY AWARD ATTORNEYS’ FEES AND COSTS TO THE PREVAILING PARTY, WHERE PERMITTED BY APPLICABLE LAW. I AGREE THAT THE DECREE OR AWARD
RENDERED BY THE ARBITRATOR MAY BE ENTERED AS A FINAL AND BINDING JUDGMENT IN ANY COURT HAVING JURISDICTION THEREOF. I UNDERSTAND THAT THE COMPANY WILL PAY FOR ANY ADMINISTRATIVE OR HEARING FEES CHARGED BY THE ARBITRATOR OR JAMS EXCEPT THAT I SHALL
PAY ANY FILING FEES ASSOCIATED WITH ANY ARBITRATION THAT I INITIATE, BUT ONLY SO MUCH OF THE FILING FEES AS I WOULD HAVE INSTEAD PAID HAD I FILED A COMPLAINT IN A COURT OF LAW THAT WOULD HAVE HAD JURISDICTION OVER SUCH COMPLAINT. I AGREE THAT THE
ARBITRATOR SHALL APPLY SUBSTANTIVE NEW HAMPSHIRE LAW TO ANY DISPUTE OR CLAIM. TO THE EXTENT THAT THE JAMS RULES CONFLICT WITH SUBSTANTIVE NEW HAMPSHIRE LAW, NEW HAMPSHIRE LAW SHALL TAKE PRECEDENCE. I AGREE THAT ANY ARBITRATION UNDER THIS AGREEMENT
SHALL BE CONDUCTED IN HILLSBOROUGH COUNTY, NEW HAMPSHIRE. 
 C. Remedy. EXCEPT FOR THE PURSUIT OF ANY PROVISIONAL
REMEDY PERMITTED UNDER THE FAA, OR AS OTHERWISE PROVIDED BY THIS AGREEMENT, I AGREE THAT ARBITRATION SHALL BE THE SOLE, EXCLUSIVE, AND FINAL REMEDY FOR ANY DISPUTE BETWEEN ME AND THE COMPANY. WHETHER IN ARBITRATION OR IN ACCORDANCE WITH THE
PROVISIONAL REMEDIES PERMITTED UNDER THE FAA, AND WHERE DEEMED APPROPRIATE BY THE JUDGE OR ARBITRATOR, BOTH PARTIES CONSENT TO THE ISSUANCE OF A TEMPORARY RESTRAINING ORDER OR PRELIMINARY INJUNCTION (INCLUDING IN THE EVENT OF ANY BREACH OR
THREATENED BREACH OF THIS AGREEMENT, WHICH WILL CAUSE IRREPARABLE INJURY AND FOR WHICH MONEY DAMAGES ALONE WILL NOT PROVIDE AN ADEQUATE REMEDY), WHICH, IN THE CASE OF A PARTY ALLEGING OR CLAIMING A VIOLATION OF AN AGREEMENT REGARDING TRADE SECRETS,
CONFIDENTIAL INFORMATION, NONCOMPETITION OR NONSOLICITATION, SHALL BE ISSUED WITHOUT THE POSTING OF A BOND. IN THE EVENT EITHER PARTY SEEKS SUCH INJUNCTIVE RELIEF, THE PREVAILING PARTY SHALL BE ENTITLED TO RECOVER REASONABLE COSTS AND
ATTORNEYS’ FEES. 
 D. Administrative Relief. I UNDERSTAND THAT THIS AGREEMENT DOES NOT PROHIBIT ME FROM PURSUING
AN ADMINISTRATIVE CLAIM WITH A LOCAL, STATE, OR FEDERAL ADMINISTRATIVE BODY OR GOVERNMENT AGENCY THAT IS AUTHORIZED TO ENFORCE OR ADMINISTER LAWS RELATED TO EMPLOYMENT, INCLUDING, BUT NOT LIMITED TO, THE NEW HAMPSHIRE COMMISSION FOR HUMAN RIGHTS,
THE EQUAL EMPLOYMENT OPPORTUNITY COMMISSION, THE NATIONAL LABOR RELATIONS BOARD, THE SECURITIES AND EXCHANGE COMMISSION, OR THE WORKERS’ COMPENSATION BOARD. THIS AGREEMENT DOES, HOWEVER, PRECLUDE ME FROM PURSUING A COURT ACTION REGARDING ANY
SUCH CLAIM, EXCEPT AS PERMITTED BY LAW. 

  
 Page 9 of 15 

 E. Voluntary Nature of Agreement. I ACKNOWLEDGE AND AGREE THAT I AM
EXECUTING THIS AGREEMENT VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE BY THE COMPANY OR ANYONE ELSE. I FURTHER ACKNOWLEDGE AND AGREE THAT I HAVE CAREFULLY READ THIS AGREEMENT AND THAT I HAVE ASKED ANY QUESTIONS NEEDED FOR ME TO UNDERSTAND
THE TERMS, CONSEQUENCES, AND BINDING EFFECT OF THIS AGREEMENT AND FULLY UNDERSTAND IT, INCLUDING THAT I AM WAIVING MY RIGHT TO A JURY TRIAL. I AGREE THAT I HAVE BEEN PROVIDED AN OPPORTUNITY TO SEEK THE ADVICE OF AN ATTORNEY OF MY
CHOICE BEFORE SIGNING THIS AGREEMENT. 
 13. MISCELLANEOUS 

A. Governing Law; Consent to Personal Jurisdiction. With the exception of the arbitration requirements set forth in
Section 12 above (which are governed by the FAA), this Agreement will be governed by the laws of the State of New Hampshire without regard to New Hampshire’
conflicts-of-law rules that may result in the application of the laws of any jurisdiction other than New Hampshire. To the extent that any lawsuit is permitted under
this Agreement, I hereby expressly consent to the personal and exclusive jurisdiction and venue of the state and federal courts located in New Hampshire for any lawsuit filed against me by the Company. 

B. Waiver of Trial by Jury. TO THE EXTENT THAT ANY LAWSUIT IS PERMITTED UNDER THIS AGREEMENT, I IRREVOCABLY AND
UNCONDITIONALLY WAIVE MY RIGHT TO A TRIAL BY JURY IN ANY LAWSUIT DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR MY RELATIONSHIP WITH THE COMPANY AND ACKNOWLEDGE THAT I AM KNOWINGLY AND VOLUNTARILY WAIVING MY RIGHT TO A TRIAL
BY JURY. 
 C. Mutual Non-Disparagement. Subject to the Protected Activity Not
Prohibited section, I agree that following the termination of my relationship with the Company, whether I resign voluntarily or am terminated by the Company involuntarily, I shall refrain from any disparagement of the Company. The Company agrees
that, following the termination of my relationship with the Company, it shall refrain from making any disparaging statements about me. I understand that the Company’s obligations under this Section 13.C extend only to the Company’s
executive officers and members of its Board of Directors at the time of my separation from the Company and only for so long as each officer or member is an employee or Director of the Company. 

D. Assignability. This Agreement will be binding upon my heirs, executors, assigns, administrators, and other legal
representatives, and will be for the benefit of the Company, its successors, and its assigns. The Associated Third Parties are intended third-party beneficiaries to this Agreement with respect to my obligations in Section 2.D. Notwithstanding
anything to the contrary herein, the Company may assign this Agreement and its rights and obligations under this Agreement to any successor to all, or substantially all, of the Company’s relevant assets, whether by merger, consolidation,
reorganization, reincorporation, sale of assets or stock, or otherwise. For the avoidance of doubt, the Company’s successors and assigns are authorized to enforce the Company’s rights under this Agreement. 

E. Entire Agreement. This Agreement, together with the Exhibits herein and any executed written offer letter between me
and the Company, to the extent such materials are not in conflict with this Agreement, sets forth the entire agreement and understanding between the Company and me with respect to the subject matter herein and supersedes all prior written and oral
agreements, discussions, or representations between us, including, but not limited to, any representations made during my interview(s) or relocation negotiations. I represent and warrant that I am not relying on any statement or representation not
contained in this Agreement. Any subsequent change or changes in my duties, salary, compensation, conditions or any other terms of my employment will not affect the validity or scope of this Agreement. 

F. Headings. Headings are used in this Agreement for reference only and shall not be considered when interpreting this
Agreement. 
 G. Severability. If a court or other body of competent jurisdiction finds, or the parties to this
Agreement mutually believe, any provision of this Agreement, or portion thereof, to be invalid or unenforceable, such provision will be enforced to the maximum extent permissible so as to effect the intent of the parties, and the remainder of this
Agreement will continue in full force and effect. 

  
 Page 10 of 15 

 H. Modification, Waiver. No modification of or amendment to this
Agreement, nor any waiver of any rights under this Agreement, will be effective unless in a writing signed by the President or CEO of the Company and me. Waiver by the Company of a breach of any provision of this Agreement will not operate as a
waiver of any other or subsequent breach. 
 I. Survivorship. The rights and obligations of the parties to this
Agreement will survive termination of my employment with the Company. 
 14. PROTECTED
ACTIVITY NOT PROHIBITED 
 I understand that nothing in
this Agreement limits or prohibits me from filing and/or pursuing a charge or complaint with, or otherwise communicating or cooperating with or participating in any investigation or proceeding that may be conducted by, any federal, state or local
government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board
(“Government Agencies”), including disclosing documents or other information as permitted by law, without giving notice to, or receiving authorization from, the Company. In addition, I understand that nothing in
this Agreement, including its definition of Company Confidential Information, (i) limits employees’ rights to discuss or disclose the terms, wages, and working conditions of their employment, nor (ii) prevents me from discussing or
disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that I have reason to believe is unlawful. Notwithstanding the preceding, I agree to take all reasonable precautions to prevent
any unauthorized use or disclosure of any Company trade secrets, proprietary information, or confidential information that does not involve unlawful acts in the workplace or the activity otherwise protected herein. I further understand that I am not
permitted to disclose the Company’s attorney-client privileged communications or attorney work product. In addition, I hereby acknowledge that the Company has provided me with notice in compliance with the Defend Trade Secrets Act of 2016
regarding immunity from liability for limited disclosures of trade secrets. The full text of the notice is attached in Exhibit B.
  

							
	 Date: September 19, 2022
	 		 		 	
                 

		 		 		 	 Signature

				
		 		 		 	 Mark Rothera

		 		 		 	 Name of Employee (typed or printed)

  
 Page 11 of 15 

 EXHIBIT A 

LIST OF PRIOR INVENTIONS 

AND ORIGINAL WORKS OF AUTHORSHIP 
  

					
	 Title
	  	 Date
	  	 Identifying Number or Brief Description

 

	☒	 No inventions or improvements 

 

	☐	 Additional Sheets Attached 

 

							
	 Date: September 19, 2022
	 		 		 	              

		 		 		 	 Signature

				
		 		 		 	 Mark Rothera

		 		 		 	 Name of Employee (typed or printed)

  
 Page 12 of 15 

 EXHIBIT B 

SECTION 7 OF THE DEFEND TRADE SECRETS ACT OF 2016 

“ . . . An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a
trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation
of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. . . . An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law
may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual—(A) files any document containing the trade secret under seal; and (B) does not disclose the
trade secret, except pursuant to court order.” 

  
 Page 13 of 15 

 EXHIBIT C 

TERMINATION CERTIFICATION 

This is to certify that I do not have in my possession, custody, or control, nor have I failed to return, any devices,
records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, any other documents or property, or reproductions of any and all aforementioned items belonging to Viracta
Therapeutics, Inc. (the “Company”). Notwithstanding the foregoing, I understand that I may keep a copy of the Company’s employee handbook and personnel records relating to me. 

I further certify that I have complied with all the terms of the Company’s Confidential Information, Invention Assignment
and Arbitration Agreement (the “Agreement”) signed by me, including the reporting of any inventions and original works of authorship (as defined therein) conceived or made by me (solely or jointly with others), as covered by that
Agreement. 
 I understand that pursuant to the Agreement, and subject to its protected activity exclusion, I am obligated
to preserve, as confidential, all Company Confidential Information and Associated Third Party Confidential Information, including trade secrets, confidential knowledge, data, or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, databases, other original works of authorship, customer lists, business plans, financial information, or other subject matter
pertaining to any business of the Company or any of its employees, clients, consultants, or licensees. 
 I also acknowledge
that under the Agreement, for twelve (12) months from this date, I will not engage in the activities prohibited by Section 8 or Section 13.C of the Agreement. After leaving the Company’s
employment, I will be employed by _______________________________________________________________ in the position of _______________________________________________________________. 

 

							
	 Date: _____________________________________
	 		 	         
	 	              

		 		 		 	 Signature

				
		 		 		 	 Mark Rothera

		 		 		 	 Name of Employee (typed or printed)

			
	 Address for Notifications:
	 		 	
             

			
		 		 	
             

  
 Page 14 of 15 

 EXHIBIT D 

CONFLICT OF INTEREST GUIDELINES 

It is the policy of Viracta Therapeutics, Inc. (the “Company”) to conduct its affairs in strict compliance
with the letter and spirit of the law and to adhere to the highest principles of business ethics. Accordingly, all officers, employees, and independent contractors must avoid activities that are in conflict, or give the appearance of being in
conflict, with these principles and with the interests of the Company. The following are potentially compromising situations that must be avoided: 

1. Revealing confidential information to outsiders or misusing confidential information. Unauthorized divulging of information
is a violation of this policy whether or not for personal gain and whether or not harm to the Company is intended. (The Confidential Information, Invention Assignment and Arbitration Agreement (“Confidentiality Agreement”), to which
this Exhibit D was attached, elaborates on this principle and is a binding agreement.) 
 2. Accepting or offering
substantial gifts, excessive entertainment, favors, or payments that may be deemed to constitute undue influence or otherwise be improper or embarrassing to the Company. 

3. Participating in civic or professional organizations that might involve divulging confidential information of the Company.

 4. Initiating or approving personnel actions affecting reward or punishment of employees or applicants where there is a
family relationship or is, or appears to be, a personal or social involvement. 
 5. Initiating or approving any form of
personal or social harassment of employees. 
 6. Investing or holding outside directorship in suppliers, customers, or
competing companies, including financial speculations, where such investment or directorship might influence in any manner a decision or course of action of the Company. 

7. Borrowing from or lending to employees, customers, or suppliers. 

8. Acquiring real estate of interest to the Company. 

9. Improperly using or disclosing to the Company any proprietary information or trade secrets of any other employer or other
person or entity with whom obligations of confidentiality exist. 
 10. Unlawfully discussing prices, costs, customers,
sales, or markets with competing companies or their employees. 
 11. Making any unlawful agreement with distributors with
respect to prices. 
 12. Improperly using or authorizing the use of any inventions that are the subject of patent claims of
any other person or entity. 
 13. Engaging in any conduct that is not in the best interest of the Company. 

Each officer, employee, and independent contractor must take every necessary action to ensure compliance with these guidelines
and to bring problem areas to the attention of higher management for review. Violations of this conflict of interest policy may result in immediate termination of employment. 

Nothing in these guidelines limits or prohibits employees from engaging in any protected activities described in the section
of the Confidentiality Agreement entitled “Protected Activity Not Prohibited.” 

  
 Page 15 of 15 

 EXHIBIT B 

INDEMNIFICATION AGREEMENT 

 VIRACTA THERAPEUTICS, INC. 

INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (the “Agreement”) is made as of September 19, 2022, by and between
Viracta Therapeutics, Inc.(formerly known as Sunesis Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), and Mark Rothera (the “Indemnitee”). 

RECITALS 

The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and
key employees, the significant increases in the cost of such insurance and the general reductions in the coverage of such insurance. The Company and Indemnitee further recognize the substantial increase in corporate litigation in general,
subjecting directors, officers and key employees to expensive litigation risks at the same time as the availability and coverage of liability insurance has been severely limited. Indemnitee does not regard the current protection available as
adequate under the present circumstances, and Indemnitee and agents of the Company may not be willing to continue to serve as agents of the Company without additional protection. The Company desires to attract and retain the services of highly
qualified individuals, such as Indemnitee, and to indemnify its directors, officers and key employees so as to provide them with the maximum protection permitted by law. 

AGREEMENT 

In consideration of the mutual promises made in this Agreement, and for other good and valuable consideration, receipt of
which is hereby acknowledged, the Company and Indemnitee hereby agree as follows: 
 1.
Indemnification. 
 (a) Third Party Proceedings. The Company shall indemnify
Indemnitee if Indemnitee is or was a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of
the Company) by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee while an officer or director or by
reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’
fees), judgments, fines and amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) actually and reasonably incurred by Indemnitee in connection with such action, suit
or proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe
Indemnitee’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that
Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or, with respect to any criminal action or proceeding, that Indemnitee had reasonable cause to
believe that Indemnitee’s conduct was unlawful. 

 (b) Proceedings By or in the Right of the
Company. The Company shall indemnify Indemnitee if Indemnitee was or is a party or is threatened to be made a party to any threatened, pending or completed action or proceeding by or in the right of the Company or any subsidiary
of the Company to procure a judgment in its favor by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee
while an officer or director or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys’ fees) and, to the fullest extent permitted by law, amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld), in each case to the
extent actually and reasonably incurred by Indemnitee in connection with the defense or settlement of such action or suit if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests
of the Company and its stockholders, except that no indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudicated by court order or judgment to be liable to the Company in the
performance of Indemnitee’s duty to the Company and its stockholders unless and only to the extent that the court in which such action or proceeding is or was pending shall determine upon application that, in view of all the circumstances of
the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper. 

(c) Mandatory Payment of Expenses. To the extent that Indemnitee has been successful on the merits or
otherwise in defense of any action, suit or proceeding referred to in Section 1(a) or Section 1(b) or the defense of any claim, issue or matter therein, Indemnitee shall be indemnified against expenses (including attorneys’ fees)
actually and reasonably incurred by Indemnitee in connection therewith. 
 2. No Employment
Rights. Nothing contained in this Agreement is intended to create in Indemnitee any right to continued employment. 

3. Expenses; Indemnification Procedure. 

(a) Advancement of Expenses. The Company shall advance all expenses incurred by Indemnitee in
connection with the investigation, defense, settlement or appeal of any civil or criminal action, suit or proceeding referred to in Section l(a) or Section 1(b) hereof (including amounts actually paid in settlement of any such action, suit
or proceeding). Indemnitee hereby undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company as authorized hereby. 

 (b) Notice/Cooperation by Indemnitee. Indemnitee
shall, as a condition precedent to his or her right to be indemnified under this Agreement, give the Company notice in writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought under this
Agreement. Notice to the Company shall be directed to the Chief Executive Officer of the Company and shall be given in accordance with the provisions of Section 12(d) below. In addition, Indemnitee shall give the Company such
information and cooperation as it may reasonably require and as shall be within Indemnitee’s power. 
 (c)
Procedure. Any indemnification and advances provided for in Section 1 and this Section 3 shall be made no later than twenty (20) days after receipt of the written request of Indemnitee. If a claim under
this Agreement, under any statute, or under any provision of the Company’s Certificate of Incorporation or Bylaws providing for indemnification, is not paid in full by the Company within twenty (20) days after a written request for payment
thereof has first been received by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the Company to recover the unpaid amount of the claim and, subject to Section 11 of this Agreement, Indemnitee shall
also be entitled to be paid for the expenses (including attorneys’ fees) of bringing such action. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in connection with any
action, suit or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Company to indemnify Indemnitee for the amount claimed, but the burden of
proving such defense shall be on the Company and Indemnitee shall be entitled to receive interim payments of expenses pursuant to Section 3(a) unless and until such defense may be finally adjudicated by court order or judgment from which no
further right of appeal exists. It is the parties’ intention that if the Company contests Indemnitee’s right to indemnification, the question of Indemnitee’s right to indemnification shall be for the court to decide, and neither
the failure of the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) to have made a determination that indemnification of Indemnitee is proper in the
circumstances because Indemnitee has met the applicable standard of conduct required by applicable law, nor an actual determination by the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent
legal counsel, or its stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct. 

(d) Notice to Insurers. If, at the time of the receipt of a notice of a claim pursuant to
Section 3(b) hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective
policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. 

 (e) Selection of Counsel. In the event the Company
shall be obligated under Section 3(a) hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel approved by Indemnitee, upon the
delivery to Indemnitee of written notice of its election so to do. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this
Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that (i) Indemnitee shall have the right to employ counsel in any such proceeding at Indemnitee’s expense; and (ii) if
(A) the employment of counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any
such defense or (C) the Company shall not, in fact, have employed counsel to assume the defense of such proceeding, then the fees and expenses of Indemnitee’s counsel shall be at the expense of the Company. 

4. Additional Indemnification Rights; Nonexclusivity. 

(a) Scope. Notwithstanding any other provision of this Agreement, the Company hereby agrees to
indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement, the Company’s Certificate of Incorporation, the Company’s
Bylaws or by statute. In the event of any change, after the date of this Agreement, in any applicable law, statute, or rule which expands the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such
changes shall be deemed to be within the purview of Indemnitee’s rights and the Company’s obligations under this Agreement. In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware
corporation to indemnify a member of its board of directors or an officer, such changes, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement shall have no effect on this Agreement or the parties’
rights and obligations hereunder. 
 (b) Nonexclusivity. The indemnification provided by this
Agreement shall not be deemed exclusive of any rights to which Indemnitee may be entitled under the Company’s Certificate of Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested members of the Company’s Board
of Directors, the General Corporation Law of the State of Delaware, or otherwise, both as to action in Indemnitee’s official capacity and as to action in another capacity while holding such office. The indemnification provided under this
Agreement shall continue as to Indemnitee for any action taken or not taken while serving in an indemnified capacity even though he or she may have ceased to serve in any such capacity at the time of any action, suit or other covered proceeding.

 5. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to
indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually or reasonably incurred in the investigation, defense, appeal or settlement of any civil or criminal action, suit or proceeding, but not,
however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled. 

 6. Mutual Acknowledgment. Both the Company and
Indemnitee acknowledge that in certain instances, Federal law or public policy may override applicable state law and prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. For example, the Company
and Indemnitee acknowledge that the Securities and Exchange Commission (the “SEC”) has taken the position that indemnification is not permissible for liabilities arising under certain federal securities laws, and federal legislation
prohibits indemnification for certain ERISA violations. Indemnitee understands and acknowledges that the Company has undertaken or may be required in the future to undertake with the SEC to submit the question of indemnification to a court in
certain circumstances for a determination of the Company’s right under public policy to indemnify Indemnitee. 
 7.
Officer and Director Liability Insurance. The Company shall, from time to time, make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or policies of insurance
with reputable insurance companies providing the officers and directors of the Company with coverage for losses from wrongful acts, or to ensure the Company’s performance of its indemnification obligations under this Agreement. Among other
considerations, the Company will weigh the costs of obtaining such insurance coverage against the protection afforded by such coverage. In all policies of director and officer liability insurance, Indemnitee shall be named as an insured in such
a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s directors, if Indemnitee is a director; or of the Company’s officers, if Indemnitee is not a director of the
Company but is an officer; or of the Company’s key employees, if Indemnitee is not an officer or director but is a key employee. Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such insurance if
the Company determines in good faith that such insurance is not reasonably available, if the premium costs for such insurance are disproportionate to the amount of coverage provided, if the coverage provided by such insurance is limited by
exclusions so as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance maintained by a parent or subsidiary of the Company. 

8. Severability. Nothing in this Agreement is intended to require or shall be construed as requiring
the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to court order, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. The provisions
of this Agreement shall be severable as provided in this Section 8. If this Agreement or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify Indemnitee
to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated, and the balance of this Agreement not so invalidated shall be enforceable in accordance with its terms. 

9. Exceptions. Any other provision herein to the contrary notwithstanding, the Company shall not be
obligated pursuant to the terms of this Agreement: 
 (a) Claims Initiated by Indemnitee. To
indemnify or advance expenses to Indemnitee with respect to proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification
under this Agreement or any other statute or law or otherwise as required under Section 145 of the Delaware General Corporation Law, but such indemnification or advancement of expenses may be provided by the Company in specific cases if the
Board of Directors finds it to be appropriate; 

 (b) Lack of Good Faith. To indemnify Indemnitee
for any expenses incurred by Indemnitee with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if a court of competent jurisdiction determines that each of the material assertions made by Indemnitee in such
proceeding was not made in good faith or was frivolous; 
 (c) Insured Claims. To indemnify Indemnitee for
expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) to the extent such expenses or liabilities have been paid directly to Indemnitee by an
insurance carrier under a policy of officers’ and directors’ liability insurance maintained by the Company; or 

(d) Claims under Section 16(b). To indemnify Indemnitee for expenses
or the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute. 

10. Construction of Certain Phrases. 

(a) For purposes of this Agreement, references to the “Company” shall include, in addition to the resulting
corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and
employees or agents, so that if Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting or surviving corporation as Indemnitee would have with respect to
such constituent corporation if its separate existence had continued. 
 (b) For purposes of this Agreement, references to
“other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to “serving at
the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit
plan, its participants, or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to
have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement. 

11. Attorneys’ Fees. In the event that any action is instituted by Indemnitee under this
Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid all court costs and expenses, including reasonable attorneys’ fees, incurred by Indemnitee with respect to such action, unless as a part of such
action, the court of competent jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such action 

 
were not made in good faith or were frivolous. In the event of an action instituted by or in the name of the Company under this Agreement or to enforce or interpret any of the terms of this
Agreement, Indemnitee shall be entitled to be paid all court costs and expenses, including attorneys’ fees, incurred by Indemnitee in defense of such action (including with respect to Indemnitee’s counterclaims and cross-claims made in
such action), unless as a part of such action the court determines that each of Indemnitee’s material defenses to such action were made in bad faith or were frivolous. 

12. Miscellaneous. 

(a) Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and
obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflict of law. 

(b) Entire Agreement; Enforcement of Rights. This Agreement sets forth the entire agreement and
understanding of the parties relating to the subject matter herein and merges all prior discussions between them. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in
writing signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party. 

(c) Construction. This Agreement is the result of negotiations between and has been reviewed by each
of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of or against any one of the parties hereto. 

(d) Notices. Any notice, demand or request required or permitted to be given under this Agreement
shall be in writing and shall be deemed sufficient when delivered personally or sent by telegram or forty-eight (48) hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party
to be notified at such party’s address as set forth below or as subsequently modified by written notice. 
 (e)
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 

(f) Successors and Assigns. This Agreement shall be binding upon the Company and its successors and
assigns, and inure to the benefit of Indemnitee and Indemnitee’s heirs, legal representatives and assigns. 
 (g)
Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all
acts that may be necessary to secure such rights and to enable the Company to effectively bring suit to enforce such rights. 

 The parties hereto have executed this Agreement as of the day and year set
forth on the first page of this Agreement. 
  

			
	 VIRACTA THERAPEUTICS, INC.

		
	 By:
	 	              

	 Name:
	 	 Roger J. Pomerantz, M.D.

	 Title:
	 	 Chairman of the Board

	
	 Address:  2533 S. Coast Hwy 101, Suite 210

	                 Cardiff,
California 92007

  

			
	 AGREED TO AND ACCEPTED:

		
	 By:
	 	              

	 Name:
	 	 Mark RotheraEX-10.2

 Exhibit 10.2 

SEPARATION AGREEMENT AND RELEASE 

This Separation Agreement and Release (“Agreement”) is made by and between Ivor Royston (“Executive”) and
Viracta Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). 

RECITALS 

WHEREAS, Executive was employed by the Company as its Chief Executive Officer; 

WHEREAS, Executive signed an Executive Employment Agreement effective as of April 3, 2017, as amended on August 12,
2021 (together, the “Employment Agreement”); 
 WHEREAS, Executive signed an
At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement with the Company (the “Confidentiality Agreement”); 

WHEREAS, Executive’s employment with the Company is being terminated effective September 19, 2022 (the
“Separation Date”); and 
 WHEREAS, the Parties wish to resolve any and all disputes, claims, complaints,
grievances, charges, actions, petitions, and demands that the Executive may have against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to
Executive’s employment with or separation from the Company. 
 NOW, THEREFORE, in consideration of the mutual promises
made herein, the Company and Executive hereby agree as follows: 
 COVENANTS 

1. Consideration. Subject to Executive’s execution and non-revocation of
this Agreement, and Executive’s continued compliance with the terms of this Agreement and the Confidentiality Agreement: 

a. Severance Payment. The Company agrees to pay Executive a total of Seven Hundred and Eight Thousand Seven Hundred and
Fifty Dollars ($708,750), at the rate of Forty Seven Thousand Two Hundred and Fifty Dollars ($47,250) per month, less applicable withholdings, for fifteen (15) months from the Separation Date, in accordance with the Company’s regular
payroll practices, with the first payment paid on the first regular payroll date following the Effective Date and to include any amounts that that otherwise would have been paid between the Separation Date and the first payment date. 

b. Health Care Coverage Payment. The Company agrees to pay Executive a total of Forty Five Thousand Nine Hundred Sixty-Two Dollars and Seventy Cents ($45,962.70), at the rate of Three Thousand Sixty-Four Dollars and Eighteen Cents ($3,064.18) per month, less applicable withholdings, for fifteen (15) months from the
Separation Date, in accordance with the Company’s regular payroll practices, with the first payment paid on the first regular payroll date following the Effective Date and to include any amounts that that otherwise would have been paid between
the Separation Date and the first payment date. In addition, the Company agrees to reimburse the Executive for the amounts he pays to continue his other Company provided health and welfare benefits (vision, dental, and life insurance) under
applicable law (COBRA) for fifteen (15) months, provided Executive timely elects and pays for continued coverage pursuant to COBRA, with such reimbursement to be made within thirty (30) days of submission of proof of payment, but only if
proof of payment is submitted within thirty (30) days of Executive paying the applicable premium. 

 c. Bonus. The Company agrees to pay Executive a pro-rated Target Bonus (as defined in the Employment Agreement) for the 2022 fiscal year, where the proration is based on the number of days between the start of the 2022 fiscal year and September 30, 2022.
Payment pursuant to this Section 1.c will be subject to the Company’s Board of Directors (the “Board”) (or an authorized committee of the Board) determining, in good faith, that any applicable performance objectives have been
achieved and, if earned, paid to Executive on the same day that 2022 annual bonuses are paid to continuing Company employees, but in no event will any such annual bonus be paid after the later of (i) the fifteenth (15th) day of the third (3rd)
month following the close of the Company’s fiscal year in which such bonus is earned or (ii) March 15 following the calendar year in which such bonus is earned. 

d. Post-Termination Exercise Period. 

i. Extension of Exercise Period. The Company agrees that, effective as of the Effective Date, the equity awards set
forth on Exhibit A (the “Options”) will each be amended to provide that Executive has the right to exercise the vested portion of each Option until the earlier of (x) two (2) years following the date that he is no longer a
Service Provider to the Company (as defined in the applicable equity incentive plan), or (y) the expiration of the term of such Option, subject in each case to earlier termination in accordance with the terms of the applicable equity incentive
plan (the “Options Amendment”). 
 ii. Tax Implications. Executive acknowledges and agrees that the Options
Amendment is a “modification” of the Options resulting in the deemed re-grant of the Options for purposes of the rules governing Incentive Stock Options under Section 422 of the Code. As a
result, the Options otherwise characterized as Incentive Stock Options have converted into Nonstatutory Stock Options for tax purposes as of the Effective Date. Upon the exercise of any of the Options, Executive will be treated as having
received compensation income from the Company (taxable at ordinary income tax rates) equal to the excess, if any, of the aggregate fair market value of the exercised shares on the date of exercise over their aggregate exercise price. In that
case, in addition to the payment of the aggregate exercise price, Executive’s exercise of any Options is conditioned on payment to the Company of applicable federal, state and other withholding obligations incurred upon exercise. Executive
acknowledges and agrees that Executive remains solely responsible for all employee-related withholdings associated with the exercise of the unexercised Options. The Company has advised the Executive to consult with Executive’s own tax
advisor regarding the tax status of the Options and the tax consequences to the Executive of Executive’s exercise of the Options and disposition of any shares acquired upon such exercise. 

e. Reimbursement of Costs and Fees. The Company shall reimburse Executive for reasonable costs and attorney’s fees
in connection with the preparation of this Agreement not to exceed $15,000 in the aggregate. 
 f. Acknowledgement.
Executive acknowledges that without this Agreement, Executive is otherwise not entitled to the consideration listed in this Section 1. 

2. Termination. Executive’s employment with the Company is being terminated as of the Separation Date. Executive
agrees to promptly execute any instruments, forms or other documents evidencing the termination of his employment as a matter of state, federal, or foreign law. 

3. Board Position. The Parties agree that Executive shall continue to be a member of the Board following the Separation
Date until the expiration of the term for which he was elected and any subsequent term for which he is nominated and elected to the Board, or until Executive’s earlier death, resignation or removal, and shall continue to vest in any outstanding
equity awards from the Company pursuant to the terms and 

 conditions of any applicable equity agreements between Executive and the Company.
Furthermore, in the event Executive otherwise would incur a termination of Continuous Service (as defined in the Company’s Amended 2011 Equity Incentive Plan) or cease to be a Service Provider (as defined in the Company’s 2021 Equity
Incentive Plan) prior to the vesting of all of the Stock Options set forth on Exhibit A due to the Executive’s removal from the Board for any reason other than his voluntary resignation, his death, or for Cause, the Company shall appoint
Executive to its Scientific Advisory Board so that Executive shall not have a termination of Continuous Service and shall continue as a Service Provider for purposes of continued vesting of the Stock Options, with Executive remaining in Continuous
Service as a Service Provider pursuant to his services as a member of the Scientific Advisory Board though the date on which the Stock Options have vested in full or his earlier voluntary resignation from the Scientific Advisory Board, death or
removal from the Scientific Advisory Board for Cause. For purposes of this Agreement, “Cause” shall mean: (i) an act of dishonesty made by Executive in connection with Executive’s responsibilities as a member of the Board or the
Scientific Advisory Board; (ii) Executive’s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude; (iii) Executive’s gross misconduct;
(iv) Executive’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Executive owes an obligation of nondisclosure as a result of Executive’s relationship with the
Company; (v) Executive’s willful breach of any obligations under any written agreement or covenant with the Company; or (vi) Executive’s continued failure to perform Executive’s Board or Scientific Advisory Board duties
after Executive has received a written demand of performance from the Company with specifically sets forth the factual basis for the Company’s belief that Executive has not substantially performed Executive’s duties and has failed to cure
such non-performance to the Company’s satisfaction within 10 business days after receiving such notice. 

4. Payment of Salary and Receipt of All Benefits. Executive’s participation in all benefits and incidents of
employment, including, but not limited to, the accrual of bonuses, vacation, and paid time off, will cease as of the Separation Date. Other than (i) the base salary otherwise payable to Executive for employment on and after September 1,
2022, (ii) Executive’s wellness (gym) benefit reimbursement for September, and (iii) payment for Executive’s accrued, but unused, vacation/paid-time off, (all of the foregoing amounts to be paid in the ordinary course), Executive
acknowledges and represents that the Company has paid or provided all salary, wages, bonuses, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, and any and all
other benefits and compensation due to Executive as of the signature date below. 
 5. Release of Claims. Executive
agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders,
administrators, affiliates, benefit plans, plan administrators, professional employer organization or co-employer, insurers, trustees, divisions, subsidiaries, predecessor and successor corporations,
and assigns (collectively, the “Releasees”). Executive, on Executive’s own behalf and on behalf of Executive’s respective heirs, family members, executors, agents, and assigns, hereby and forever releases the Releasees from, and
agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or
unsuspected, that Executive may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the date Executive signs this Agreement, including, without limitation: 

a. any and all claims relating to or arising from Executive’s employment relationship with the Company and the termination
of that relationship; 
 b. any and all claims relating to, or arising from, Executive’s right to purchase, or actual
purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;

 c. any and all claims for wrongful discharge of employment, termination in
violation of public policy, discrimination, harassment, retaliation, breach of contract (both express and implied), breach of covenant of good faith and fair dealing (both express and implied), promissory estoppel, negligent or intentional
infliction of emotional distress, fraud, negligent or intentional misrepresentation, negligent or intentional interference with contract or prospective economic advantage, unfair business practices, defamation, libel, slander, negligence, personal
injury, assault, battery, invasion of privacy, false imprisonment, conversion, and disability benefits; 
 d. any and all
claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Rehabilitation Act of 1973, the Americans with Disabilities Act of
1990, the Equal Pay Act, the Fair Labor Standards Act, the Fair Credit Reporting Act, the Age Discrimination in Employment Act of 1967, the Older Workers Benefit Protection Act, the Employee Retirement Income Security Act of 1974, the Worker
Adjustment and Retraining Notification Act, the Family and Medical Leave Act, the Immigration Reform and Control Act, the National Labor Relations Act, the California Family Rights Act, the California Labor Code, the California Workers’
Compensation Act, and the California Fair Employment and Housing Act; 
 e. any and all claims for violation of the federal
or any state constitution; 
 f. any and all claims arising out of any other laws and regulations relating to employment or
employment discrimination; 
 g. any claim for any loss, cost, damage, or expense arising out of any dispute over the
nonwithholding or other tax treatment of any of the proceeds received by Executive as a result of this Agreement; and 
 h.
any and all claims for attorneys’ fees and costs. 
 Executive agrees that the release set forth in this section shall be and remain in
effect in all respects as a complete general release as to the matters released. This release does not extend to any obligations incurred under this Agreement. This release does not release claims that cannot be released as a matter of law. This
release does not waive any rights available to Executive under the Indemnification Agreement signed between the Parties on February 24, 2021 (the “Indemnification Agreement”). This release does not release claims Executive may have in
connection with his status as a stockholder. Any and all disputed wage claims that are released herein shall be subject to binding arbitration in accordance with this Agreement, except as required by applicable law. This release does not extend to
any right Executive may have to unemployment compensation benefits. 
 6. Acknowledgment of Waiver of Claims under
ADEA. Executive acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is knowing and voluntary. Executive
agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the date Executive signs this Agreement. Executive acknowledges that the consideration given for this waiver and release is in addition to
anything of value to which Executive was already entitled. Executive further acknowledges that Executive has been advised by this writing that: (a) Executive should consult with an attorney prior to executing this Agreement;
(b) Executive has twenty-one (21) days within which to consider this Agreement; (c) Executive has seven (7) days following Executive’s execution of this Agreement to revoke this
Agreement; (d) this Agreement 

 
shall not be effective until after the revocation period has expired; and (e) nothing in this Agreement prevents or precludes Executive from challenging or seeking a determination in good
faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Agreement and returns it to the
Company in less than the 21-day period identified above, Executive hereby acknowledges that Executive has knowingly and voluntarily chosen to waive the time period allotted for considering this Agreement.
Executive acknowledges and understands that revocation must be accomplished by a written notification to the person executing this Agreement on the Company’s behalf that is received prior to the Effective Date. The Parties agree that changes,
whether material or immaterial, do not restart the running of the 21-day period. 

7. California Civil Code Section 1542. Executive acknowledges that Executive has been advised to
consult with legal counsel and is familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides as follows: 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR
HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY. 

Executive, being aware of said code section, agrees to expressly waive any rights Executive may have thereunder, as well as under any other
statute or common law principles of similar effect. 
 8. No Pending or Future Lawsuits. Executive represents that
Executive has no lawsuits, claims, or actions pending in Executive’s name, or on behalf of any other person or entity, against the Company or any of the other Releasees. Executive also represents that Executive does not currently intend to
bring any claims on Executive’s own behalf or on behalf of any other person or entity against the Company or any of the other Releasees. 

9. Application for Employment. Executive understands and agrees that, as a condition of this Agreement, Executive shall
not be entitled to any employment with the Company, and Executive hereby waives any right, or alleged right, of employment or re-employment with the Company. 

10. Trade Secrets and Confidential Information/Company Property. Executive agrees at all times hereafter to hold in the
strictest confidence, and not to use or disclose to any person or entity, any Confidential Information of the Company. Executive understands that “Confidential Information” means any Company or associated third party proprietary
information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customer lists and customers (including, but not limited to, customers of the
Company on whom Executive has called or with whom Executive became acquainted during the term of Executive’s employment), markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware
configuration information, marketing, finances, or other business information disclosed to Executive by the Company either directly or indirectly, in writing, orally, or by drawings or observation of parts or equipment. Executive further understands
that Confidential Information does not include any of the foregoing items that have become publicly known and made generally available through no wrongful act of Executive’s or of others who were under confidentiality obligations as to the item
or items involved or improvements or new versions thereof. Executive hereby grants consent to notification by the Company to any new employer about Executive’s obligations under this section. Executive represents that Executive has not to date
misused or disclosed Confidential Information to any unauthorized party. Executive acknowledges that the Company will not enforce the post-employment non-solicitation restrictions in the Confidentiality
Agreement; provided, however, that Executive remains bound by all other continuing 

 
obligations under the Confidentiality Agreement, including Executive’s confidentiality obligations thereof. Executive’s signature below constitutes Executive’s certification under
penalty of perjury that Executive has returned all documents and other items provided to Executive by the Company, developed or obtained by Executive in connection with Executive’s employment with the Company, or otherwise belonging to the
Company, except as stated herein. Specifically, Executive may retain a copy of the Employee Handbook and personnel documents specifically relating to Executive. In addition, during the period in which Executive continues to serve as a member of the
Board or is otherwise a Company service provider, subject to his continuing obligations under the Confidentiality Agreement (as amended herein) and this Agreement, applicable Company security and cybersecurity policies as may be amended or adopted
from time to time, and other applicable legal obligations, Executive will: (i) have access to, and may continue using, his Company-provided email account, (ii) retain his Company-issued desktop computer and have continued access to the
Company’s Active Directory Controlled Network accessible folder, and (iii) retain his Company-issued phone and phone number. 

11. Invention Assignment. 

a. Inventions Defined. “Inventions” means inventions, original works of authorship, developments, concepts,
improvements, designs, discoveries, ideas, know-how, trademarks, and trade secrets, whether or not patentable or registrable under copyright or similar laws, that Executive solely or jointly authored,
conceived, developed, or reduced to practice. 
 b. Assignment of Inventions and Works Made for Hire. Executive hereby
assigns to Company, or its designee, all of Executive’s right, title, and interest (including all related intellectual property rights) in all Inventions that Executive created during the period of time Executive was in the employ of the
Company (including during off-duty hours) (“Company Inventions”). In addition, Executive acknowledges that all original works of authorship that were made by Executive (solely or jointly with others)
within the scope of and during the period of Executive’s employment with Company and that are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act, and in accordance, the
Company is considered the author of these works. 
 c. Exception to Assignments. EXECUTIVE ACKNOWLEDGES AND
UNDERSTANDS THAT THE PROVISIONS OF THIS AGREEMENT REQUIRING ASSIGNMENT OF INVENTIONS TO COMPANY DO NOT APPLY TO ANY INVENTION THAT QUALIFIES FULLY UNDER THE PROVISIONS OF CALIFORNIA LABOR CODE SECTION 2870. California Labor Code section 2870
provides: “(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee
developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) Relate at the time of conception or reduction to practice of
the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or (2) Result from any work performed by the employee for the employer. (b) To the extent a provision in an
employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.” 

d. Outside Inventions. Executive acknowledges that Executive has not incorporated any inventions, discoveries,
ideas, original works of authorship, developments, improvements, trade secrets and other proprietary information or intellectual property rights owned by any third party into any Company Invention without the Company’s prior written permission.
Executive acknowledges that Executive has informed the Company, in writing, before incorporating any inventions, discoveries, ideas, original works of authorship, developments, improvements, trade secrets and other proprietary information or
intellectual property 

 
rights owned by Executive or in which Executive has an interest prior to, or separate from, Executive’s employment with the Company, including, without limitation, any such inventions that
are subject to California Labor Code Section 2870 (“Outside Inventions”) into any Company Invention or otherwise utilizing any Outside Invention in the course of Executive’s employment with the Company; and the Company is hereby
granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable worldwide license (with the right to grant and authorize sublicenses) to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare
derivative works of, display, perform, and otherwise exploit any such incorporated or utilized Outside Inventions, without restriction, including, without limitation, as part of, or in connection with, such Invention, and to practice any method
related thereto. 
 e. Moral Rights. Any assignment to the Company of Company Inventions includes all rights of
attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” or the like (collectively,
“Moral Rights”). If Moral Rights cannot be assigned under applicable law, Executive hereby waives and agrees not to enforce any and all Moral Rights, including any limitation on subsequent modification, to the extent permitted under
applicable law. 
 f. Further Assurances. Executive will assist the Company, or its designee, at Company’s
expense, in every proper way to secure and protect the Company’s rights in Company Inventions and any related copyrights, patents, mask work rights, or other intellectual property rights in any and all countries. Executive will disclose to
Company all pertinent information and data. Executive will execute all applications, specifications, oaths, assignments, and all other instruments that Company deems necessary in order to apply for and obtain these rights and in order to deliver,
assign, and convey to Company, its successors, assigns, and nominees the sole and exclusive rights, title, and interest in and to Company Inventions, and any related copyrights, patents, mask work rights, or other intellectual property rights.
Executive will testify in a suit or other proceeding relating to such Company Inventions and any rights relating thereto. 

12. No Cooperation. Subject to the Protected Activity Not Prohibited section, Executive agrees that Executive will not
knowingly encourage, counsel, or assist any attorneys or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against any of the Releasees, unless under a
subpoena or other court order to do so or upon written request from an administrative agency or the legislature or as related directly to the ADEA waiver in this Agreement Executive agrees both to immediately notify the Company upon receipt of any
such subpoena or court order or written request from an administrative agency or the legislature, and to furnish, within three (3) business days of its receipt, a copy of such subpoena or other court order or written request from an
administrative agency or the legislature. If approached by anyone for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints against any of the Releasees, Executive shall
state no more than that Executive cannot provide counsel or assistance. 
 13. Protected Activity Not Prohibited.
Executive understands that nothing in this Agreement shall in any way limit or prohibit Executive from engaging in any Protected Activity. Protected Activity includes: (i) filing and/or pursuing a charge, complaint, or report with, or otherwise
communicating, cooperating, or participating in any investigation or proceeding that may be conducted by any federal, state or local government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity
Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board (“Government Agencies”); and/or (ii) discussing or disclosing information about unlawful acts in the workplace, such as harassment
or discrimination or any other conduct that Executive has reason to believe is unlawful. Executive understands that in connection with such Protected Activity, Executive is permitted to disclose documents or other information as permitted by law,
without giving notice to, or receiving authorization from, the Company. Notwithstanding the foregoing, Executive agrees to take all reasonable 

 
precautions to prevent any unauthorized use or disclosure of any Company trade secrets, proprietary information, or confidential information that does not involve unlawful acts in the workplace
or the activity otherwise protected herein. Executive further understands that Protected Activity does not include the disclosure of any Company attorney-client privileged communications or attorney work product. Any language in the Confidentiality
Agreement regarding Executive’s right to engage in Protected Activity that conflicts with, or is contrary to, this section is superseded by this Agreement. In addition, pursuant to the Defend Trade Secrets Act of 2016, Executive is notified
that an individual will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government official (directly or
indirectly) or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing is
made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the individual’s attorney and use the trade secret information in the
court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order. 

14. Mutual Nondisparagement. Subject to the Protected Activity Not Prohibited section, Executive agrees to refrain from
any disparagement, defamation, libel, or slander of any of the Releasees, and agrees to refrain from any tortious interference with the contracts and relationships of any of the Releasees. Similarly, the Company agrees to refrain from any
disparagement, defamation, libel or slander of Executive. Executive understands that the Company’s obligations under this paragraph extend only to the Company’s current executive officers and members of its Board of Directors and only for
so long as each officer or member is an employee or director of the Company. Executive shall direct any inquiries by potential future employers to the Company’s human resources department. 

15. Breach. In addition to the rights provided in the “Attorneys’ Fees” section below, Executive
acknowledges and agrees that any material breach of this Agreement, unless such breach constitutes a legal action by Executive challenging or seeking a determination in good faith of the validity of the waiver herein under the ADEA, or of any
provision of the Confidentiality Agreement (as amended herein) shall entitle the Company immediately to recover and/or cease providing the consideration provided to Executive under this Agreement and to obtain damages, except as provided by law.

 16. No Admission of Liability. Executive understands and acknowledges that with respect to all claims released
herein, this Agreement constitutes a compromise and settlement of any and all actual or potential disputed claims by Executive unless such claims were explicitly not released by the release in this Agreement. No action taken by the Company hereto,
either previously or in connection with this Agreement, shall be deemed or construed to be (a) an admission of the truth or falsity of any actual or potential claims or (b) an acknowledgment or admission by the Company of any fault or
liability whatsoever to Executive or to any third party. 
 17. ARBITRATION. EXCEPT AS PROHIBITED BY LAW, THE PARTIES
AGREE THAT ANY AND ALL DISPUTES ARISING OUT OF THE TERMS OF THIS AGREEMENT, THEIR INTERPRETATION, EXECUTIVE’S EMPLOYMENT WITH THE COMPANY OR THE TERMS THEREOF, OR ANY OF THE MATTERS HEREIN RELEASED, SHALL BE SUBJECT TO ARBITRATION UNDER THE
FEDERAL ARBITRATION ACT (THE “FAA”) AND THAT THE FAA SHALL GOVERN AND APPLY TO THIS ARBITRATION AGREEMENT WITH FULL FORCE AND EFFECT; HOWEVER, WITHOUT LIMITING ANY PROVISIONS OF THE FAA, A MOTION OR PETITION OR ACTION TO COMPEL ARBITRATION
MAY ALSO BE BROUGHT IN STATE COURT UNDER THE PROCEDURAL PROVISIONS OF SUCH STATE’S LAWS RELATING TO MOTIONS OR PETITIONS OR ACTIONS TO COMPEL ARBITRATION. EXECUTIVE AGREES THAT, TO THE FULLEST EXTENT PERMITTED BY 

 
LAW, EXECUTIVE MAY BRING ANY SUCH ARBITRATION PROCEEDING ONLY IN EXECUTIVE’S INDIVIDUAL CAPACITY. ANY ARBITRATION WILL OCCUR IN SAN DIEGO COUNTY, BEFORE JAMS, PURSUANT TO ITS EMPLOYMENT
ARBITRATION RULES & PROCEDURES (“JAMS RULES”), EXCEPT AS EXPRESSLY PROVIDED IN THIS SECTION. THE PARTIES AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO DECIDE ANY MOTIONS BROUGHT BY ANY PARTY TO THE ARBITRATION, INCLUDING
MOTIONS FOR SUMMARY JUDGMENT AND/OR ADJUDICATION, AND MOTIONS TO DISMISS AND DEMURRERS, APPLYING THE STANDARDS SET FORTH UNDER THE CALIFORNIA CODE OF CIVIL PROCEDURE. THE PARTIES AGREE THAT THE ARBITRATOR SHALL ISSUE A WRITTEN DECISION ON THE
MERITS. THE PARTIES ALSO AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO AWARD ANY REMEDIES AVAILABLE UNDER APPLICABLE LAW, AND THAT THE ARBITRATOR MAY AWARD ATTORNEYS’ FEES AND COSTS TO THE PREVAILING PARTY, WHERE PERMITTED BY APPLICABLE
LAW. THE ARBITRATOR MAY GRANT INJUNCTIONS AND OTHER RELIEF IN SUCH DISPUTES. THE DECISION OF THE ARBITRATOR SHALL BE FINAL, CONCLUSIVE, AND BINDING ON THE PARTIES TO THE ARBITRATION. THE PARTIES AGREE THAT THE PREVAILING PARTY IN ANY ARBITRATION
SHALL BE ENTITLED TO INJUNCTIVE RELIEF IN ANY COURT OF COMPETENT JURISDICTION TO ENFORCE THE ARBITRATION AWARD. THE PARTIES TO THE ARBITRATION SHALL EACH PAY AN EQUAL SHARE OF THE COSTS AND EXPENSES OF SUCH ARBITRATION, AND EACH PARTY SHALL
SEPARATELY PAY FOR ITS RESPECTIVE COUNSEL FEES AND EXPENSES; PROVIDED, HOWEVER, THAT THE ARBITRATOR MAY AWARD ATTORNEYS’ FEES AND COSTS TO THE PREVAILING PARTY, EXCEPT AS PROHIBITED BY LAW. THE PARTIES HEREBY AGREE TO WAIVE THEIR RIGHT TO HAVE
ANY DISPUTE BETWEEN THEM RESOLVED IN A COURT OF LAW BY A JUDGE OR JURY. NOTWITHSTANDING THE FOREGOING, THIS SECTION WILL NOT PREVENT EITHER PARTY FROM SEEKING INJUNCTIVE RELIEF (OR ANY OTHER PROVISIONAL REMEDY) FROM ANY COURT HAVING JURISDICTION
OVER THE PARTIES AND THE SUBJECT MATTER OF THEIR DISPUTE RELATING TO THIS AGREEMENT AND THE AGREEMENTS INCORPORATED HEREIN BY REFERENCE. SHOULD ANY PART OF THE ARBITRATION AGREEMENT CONTAINED IN THIS SECTION CONFLICT WITH ANY OTHER ARBITRATION
AGREEMENT BETWEEN THE PARTIES, INCLUDING, BUT NOT LIMITED TO THE ARBITRATION SECTION OF THE CONFIDENTIALITY AGREEMENT, THE PARTIES AGREE THAT THIS ARBITRATION AGREEMENT IN THIS SECTION SHALL GOVERN. 

18. Tax Consequences. The Company makes no representations or warranties with respect to the tax consequences of the
payments and any other consideration provided to Executive or made on Executive’s behalf under the terms of this Agreement. The Parties agree and acknowledge that the payments made pursuant to section 1 of this Agreement are not related to
sexual harassment or sexual abuse and not intended to fall within the scope of 26 U.S.C. Section 162(q). The Company shall withhold on the payments to be made hereunder in accordance with applicable law. 

19. Section 409A. It is intended that this Agreement comply with, or be exempt from, Code Section 409A and the
final regulations and official guidance thereunder (“Section 409A”) and any ambiguities herein will be interpreted to so comply and/or be exempt from Section 409A. Each payment and benefit to be paid or provided under this
Agreement is intended to constitute a series of separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. The Company and Executive will work together in good faith to consider
either (i) amendments to this Agreement; or (ii) revisions to this Agreement with respect to the payment of any awards, which are necessary or appropriate to avoid imposition of any additional tax or income recognition prior to the actual
payment to Executive under Section 409A. In no event will the Releasees reimburse Executive for any taxes that may be imposed on Executive as a result of Section 409A. The parties acknowledge and agree that the termination of
Executive’s employment constitutes a “separation from service” under Section 409A of the Code. Notwithstanding anything to the contrary in this Agreement, if Executive is a 

 
“specified employee” within the meaning of Section 409A at the time of Executive’s termination of employment (other than due to death), and if necessary to avoid the
imputation of additional tax, whether in the form of excise taxes or otherwise, pursuant to Section 409A, then all amounts payable hereunder that are considered deferred compensation under Section 409A (“Deferred Compensation
Separation Benefits”) that are payable within the first six (6) months following Executive’s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one
(1) day following the date of Executive’s separation from service. Notwithstanding anything herein to the contrary, if Executive dies following Executive’s separation from service, but prior to the six (6) month anniversary of
the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive’s death and all other Deferred Compensation Separation
Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. 
 20.
Authority. The Company represents and warrants that the undersigned has the authority to act on behalf of the Company and to bind the Company and all who may claim through it to the terms and conditions of this Agreement. Executive represents
and warrants that Executive has the capacity to act on Executive’s own behalf and on behalf of all who might claim through Executive to bind them to the terms and conditions of this Agreement. Each Party warrants and represents that there are
no liens or claims of lien or assignments in law or equity or otherwise of or against any of the claims or causes of action released herein. 

21. Severability. In the event that any provision or any portion of any provision hereof or any surviving agreement made
a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision. 

22. Attorneys’ Fees. Except with regard to a legal action challenging or seeking a determination in
good faith of the validity of the waiver herein under the ADEA, in the event that either Party brings an action to enforce or effect its rights under this Agreement, the prevailing Party shall be entitled to recover its costs and expenses, including
the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys’ fees incurred in connection with such an action. 

23. Entire Agreement. This Agreement represents the entire agreement and understanding between the Company and Executive
concerning the subject matter of this Agreement and Executive’s employment with and separation from the Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings
concerning the subject matter of this Agreement and Executive’s relationship with the Company, including, but not limited to, the Employment Agreement, with the exception of the Confidentiality Agreement and the Indemnification Agreement,
except as amended herein. 
 24. No Oral Modification. This Agreement may only be amended in a writing signed by
Executive and the Company’s Chairman of the Board. 
 25. Governing Law. This Agreement shall be governed by the
laws of the State of California, without regard for choice-of-law provisions, except that any dispute regarding the enforceability of the arbitration section of this
Agreement shall be governed by the FAA. Executive consents to personal and exclusive jurisdiction and venue in the State of California. 

26. Effective Date. Executive understands that this Agreement shall be null and void if not executed by Executive within
twenty-one (21) days. Each Party has seven (7) days after that Party signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Executive signed this
Agreement, so long as it has been signed by the Parties and has not been revoked by either Party before that date (the “Effective Date”). 

 27. Counterparts. This Agreement may be executed in counterparts and
each counterpart shall be deemed an original and all of which counterparts taken together shall have the same force and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned. The
counterparts of this Agreement may be executed and delivered by facsimile, photo, email PDF, or other electronic transmission or signature. 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS] 

 28. Voluntary Execution of Agreement. Executive understands and
agrees that Executive executed this Agreement voluntarily and without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive’s claims against the Company and any
of the other Releasees. Executive acknowledges that: 
  

	 	(a)	 Executive has read this Agreement; 

 

	 	(b)	 Executive has a right to consult with an attorney regarding this Agreement, and has been represented in the
preparation, negotiation, and execution of this Agreement by an attorney of Executive’s own choice or has elected not to retain an attorney; 

  

	 	(c)	 Executive understands the terms and consequences of this Agreement and of the releases it contains;

  

	 	(d)	 Executive is fully aware of the legal and binding effect of this Agreement; and 

 

	 	(e)	 Executive has not relied upon any representations or statements made by the Company that are not
specifically set forth in this Agreement. 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on the
respective dates set forth below. 
  

							
		 		 	 IVOR ROYSTON, M.D., an individual

			
	 Dated: September 15, 2022
	 		 	 /s/ Ivor Royston, M.D.

		 		 	 Ivor Royston, M.D.

			
		 		 	 VIRACTA THERAPEUTICS, INC.

				
	 Dated: September 15, 2022
	 		 	 By
	 	 /s/ Roger J. Pomerantz, M.D.

		 		 		 	 Roger J. Pomerantz, M.D.

		 		 		 	 Chairman of the Board

 Exhibit A 

 

																							
	Grant Date	 	  	Equity Plan	 	  	Shares Subject
to Original
Option	 	  	Exercise Price	 	  	Shares
Previously
Exercised	 	  	Outstanding
Shares Subject
to Option	 
	 	02/13/2019	 	  	 	2016 Plan	 	  	 	123,750	 	  	$	0.90	 	  	 	62,950	 	  	 	60,800	 
	 	01/08/2021	 	  	 	2016 Plan	 	  	 	201,751	 	  	$	3.58	 	  	 	0	 	  	 	201,751	 
	 	03/26/2021	 	  	 	2021 Plan	 	  	 	441,993	 	  	$	8.74	 	  	 	0	 	  	 	441,993	 
	 	03/17/2022	 	  	 	2021 Plan	 	  	 	412,500	 	  	$	3.04	 	  	 	0	 	  	 	412,500

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]